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ABSTRACT 
THE RETINOBLASTOMA PROTEIN MEDIATES METABOLIC 
REPROGRAMMING IN LUNG CANCER 
Lindsey R. Conroy 
January 24, 2020 
Lung cancer is among the most frequently diagnosed cancers and is the 
leading cause of cancer-related deaths worldwide. One of the hallmark events in 
lung cancer pathogenesis is deregulation of the cell cycle. The retinoblastoma 
protein (pRb) is a tumor suppressor that is deleted, mutated, or inactivated in most 
lung cancer cases. Canonically, pRb functions to regulate cell cycle progression 
by repressing the transcriptional activity of the E2F family of transcription factors, 
inhibiting S phase entry. Although the cell cycle functions of pRb have been well 
established, recent studies have highlighted a functional role for pRb in controlling 
cellular metabolism. This body of work describes the role of pRb in mediating 
metabolic reprogramming in both in vitro and in vivo models of lung cancer.  
To define metabolic pathways regulated by pRb in vitro, I performed several 
metabolic assays and stable-isotope labeled metabolomics studies in A549 lung 
adenocarcinoma cells. pRb activity was manipulated via treatment with palbociclib, 
a CDK4/6 inhibitor which inhibits the phosphorylation and subsequent inactivation 
of pRb. Palbociclib decreases nucleotide biosynthesis by reducing activity of 
vi 
glucose 6-phosphate dehydrogenase, the rate limiting enzyme in the pentose 
phosphate pathway (PPP), without altering glycolysis. Additionally, palbociclib 
increases glutamine dependency for mitochondrial function and sensitizes A549 
cells to the glutaminase inhibitor, CB-839. The effects of palbociclib on both the 
PPP and glutamine utilization occur in an pRb-dependent manner.  
Separately, using a combination of steady-state and stable-isotope labeled 
metabolomics, I assessed global changes in metabolism resulting from the loss of 
the gene encoding pRb (Rb1) in Kras-driven lung tumors in vivo. Depletion of Rb1 
in a mutant Kras-driven mouse model of lung cancer enhances glucose 
metabolism, via upregulation of key genes within glycolysis, without altering 
mitochondrial pyruvate oxidation. Moreover, pRb-deficient tumors do not exhibit 
alterations in glutamine anaplerosis or utilization of alternative nutrient sources 
(e.g. circulating lactate) compared to lung tumors with intact pRb.  
Together the work described in this dissertation expands our knowledge of 
the metabolic phenotype resulting from pRb dysfunction in lung cancer, and 
highlights specific metabolic perturbations that may be exploited therapeutically 
based on pRb status in patient lung tumors.   
vii 
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CHAPTER 1: INTRODUCTION 
Lung Cancer 
Lung cancer is among the most frequently diagnosed cancers and is the 
leading cause of cancer-related mortality worldwide, with an estimated 1.6 million 
deaths each year (1-3). The overall five-year survival rate for lung cancer patients 
is only 18%, with more than half of these patients succumbing to their disease 
within the first year of diagnosis (1). The most common risk factor for developing 
lung cancer is tobacco smoking, which comprises over 80% of all cases in the 
United States as well as other countries with prevalent tobacco use (4). However, 
environmental exposures including second-hand smoke, radon, air pollution, 
occupational carcinogens, and genetic susceptibility have a role in lung cancer 
development (2,5,6). Approximately 85% of patients are diagnosed with having 
non-small cell lung cancer (NSCLC), of which lung adenocarcinoma (LUAD) and 
lung squamous cell carcinoma (LUSC) are the most common subtypes, while small 
cell lung cancer (SCLC) accounts for the remaining 15% of diagnoses (3). Each 
subtype has distinct oncogenic drivers, epidemiology, and therapeutic options, 
which differentially impact patient outcomes. This dissertation will focus on the 
NSCLC subtype as it is accounts for the majority of lung cancer diagnoses.  
A NSCLC diagnosis is defined by the TNM staging system, where stage is 




and distant metastasis (M) (7). Common metastasis sites for NSCLC are the brain, 
liver, and bone (8). Often, NSCLC is detected at more advanced-stages, resulting 
in a poorer clinical outcome for patients; however, this is beginning to improve with 
better screening methods and more efficacious therapies (1,2,4,7). Over the past 
two decades, the treatment of lung cancer has changed from the use of non-
specific cytotoxic therapies to targeted or personalized strategies based on the 
genetic alterations of the patient’s tumor (5). Among the many cellular processes 
genetically altered during lung cancer pathogenesis, the most prevalent involves 
disruption of cell cycle control.  
The Cell Cycle 
 The mammalian cell cycle is comprised of five sequential phases: G0, G1, 
S, G2, and M. During two of these phases, cells must complete two fundamental 
events to ensure proper cell division. First, in S phase, the cell must generate a 
single and faithful copy of its genetic material, while in M phase, the cell must 
partition all of its cellular compartments into two identical daughter cells. The two 
other phases of the cell cycle, G1 and G2, are considered “gap” phases. During 
these times, cells prepare themselves for successful entry and completion of the 
S and M phases, respectively. In the absence of mitogenic signaling or when cells 
cease proliferation, they exit the cell cycle and remain in G0. In this non-dividing 
phase, cells are referred to as quiescent, or in a state of cell cycle arrest. Cells in 
G0 account for the majority of non-proliferative cells in the human body.  
 Over the last several decades, extensive research has been conducted on 




players of cell cycle progression are the cyclin-dependent kinases (CDKs). The 
activity of these serine/threonine kinases is tightly regulated by their ability to form 
complexes with larger proteins called cyclins. Transitioning from one cell cycle 
phase to the next occurs in an orderly fashion due to the different cyclin-CDK 
complexes that form and activate their respective downstream targets during 
specific cell cycle phases (9). Timely activation of cyclin-CDK complexes is 
controlled by expression of the INK4 and the kinase inhibitory (WAF/KIP) family of 
proteins, which inhibit the association of CDKs with cyclins (10). In addition to 
cyclin-CDK regulation, there are several cell cycle checkpoints in place that ensure 
cells preserve genome integrity and chromosomal stability (11).  
G1 to S Phase Transition 
 Quiescent cells (G0) enter the cell cycle in response to mitogenic or growth 
factor signals, resulting in increased intracellular levels of D-type cyclins (D1-3). 
Cyclin D then localizes to the nucleus where it forms active Cyclin D-CDK4 or 
Cyclin D-CDK6 complexes that phosphorylate the retinoblastoma protein [pRb, 
RB1(gene), also referred to as Rb] and other members of the “pocket” protein 
family (12,13). The pRb pocket proteins (pRb, p107, and p130) negatively regulate 
the transition from G1 to S phase by binding to the E2F family of transcription 
factors and repressing the expression of genes required for cellular processes, 
including DNA replication (14). Phosphorylation of pRb by Cyclin D-CDK4/6 
complexes induces a conformational change that promotes its dissociation from 
E2Fs, thereby enabling the transcription of genes required for DNA synthesis and 







Figure 1. Schematic of Rb in cell cycle control. In early G1, Rb physically 
associates with E2F transcription factors, blocking their transactivation domain. In 
late G1, Rb phosphorylation releases E2Fs, allowing the expression of genes that 
encode products necessary for S-phase progression. Rb and p-Rb indicate 
unphosphorylated and phosphorylated Rb, respectively (15). Reprinted with 
permission from [Springer Nature] : [Nature] [NATURE REVIEWS CANCER] 
(Tailoring to RB: tumour suppressor status and therapeutic response, Erik S. 







during the late G1 phase by the cyclin E-CDK2 complex, which  reinforces pRb 
inactivation and irreversible initiation of the gene expression program of S phase 
(11,16). This stage is referred to as the restriction point. Alterations of the 
molecular players involved in the restriction point are crucial for cancer initiation, 
as it allows cancer cells to proliferate independently of mitogenic or growth factor 
stimuli.  
Alterations of the pRb-E2F Pathway in Lung Cancer 
 Genetic alterations of the G1 to S phase transition have been reported to 
play a key role in the pathogenesis and progression of both NSCLC and SCLC via 
very different mechanisms (11). In SCLC, pRb is inactivated in more than 90% of 
cases as a result of point mutations and abnormal mRNA expression (17). 
Conversely, the majority of NSCLC cases exhibit abnormalities in the upstream 
regulators of pRb, such as overexpression of Cyclin D1 or deletion of the p16INK4A 
gene, which results in increased cyclin-CDK activity and pRb constitutive 
inactivation through hyperphosphorylation (18,19). p16INK4A loss and Cyclin D1 
overexpression are always inversely correlated with RB1 loss, suggesting they 
exert their activities via pRb during lung transformation. Additionally, RB1 is 
mutated in 15-30% of NSCLC cases, which correlates to poorer overall survival for 
these patients.  
Given the prevalence of aberrations in cell cycle control in lung tumors, 
modulation of the cell cycle machinery has become an important therapeutic 
strategy for the treatment of lung cancer. As discussed above, CDKs are often 




progression, in part through inactivating pRb. As such, selective inhibition of CDKs 
has the potential to inhibit tumor cell proliferation by inducing cell cycle arrest (11). 
Over the past three decades, extensive research has been done to develop small 
molecule inhibitors of CDKs. First generation pan-CDK inhibitors evaluated in 
clinical trials showed partial responses in NSCLC patients when combined with 
standard cytotoxic agents; however, their toxicity and low activity excluded them 
from being FDA approved (20). Further investigation has shifted from the use of 
general pan-CDK inhibitors to the development of compounds that target specific 
CDKs. Among these inhibitors, palbociclib (PD-0332991), a potent small-molecule 
CDK4/6 inhibitor has been FDA-approved for the treatment of women with breast 
cancer (21), and has shown efficacy in preclinical studies of NSCLC (22-26).  
Canonical & Noncanonical Functions of the Retinoblastoma Protein  
 The RB1 gene product was initially discovered in retinoblastomas and is the 
first reported tumor suppressor protein (27). In addition to retinoblastoma, genetic 
alterations of RB1 have been found in osteosarcomas, renal cell carcinomas, as 
well as adenocarcinomas of the breast, prostate, cervix, and lung (SCLC) (27). 
Even in cancers without mutations or deletion of RB1 itself, disruption of other 
nodes of the pRb-E2F pathways are observed, suggesting loss of pRb function is 
a hallmark of human cancer (28). Following its discovery, extensive 
characterization has been done on pRb’s role in cell cycle progression. In addition 
to its interaction with the E2F family of transcription factors, pRb has been found 
to associate with over 100 proteins, including a variety of transcription factors and 




that can either repress or activate transcription (30-32). Due to its broad range of 
binding partners, the direct targets of pRb activity are diverse and regulate other 
processes such as differentiation, angiogenesis, genome stability, and apoptosis 
(Figure 2) (33). Beyond cell cycle, other dysregulated cellular activities contribute 
to malignant immortalization and transformation of normal lung tissue. Most of 
these are intimately connected, such as cell cycle control and metabolic regulation. 
Nutrient metabolism provides the required intermediates that allow cell cycle 
progression, so accordingly alterations in metabolic pathways are observed in the 
vast majority of human cancers.   
Cancer Metabolism  
Metabolism describes the complex, integrated network of chemical 
reactions in which macromolecules are broken down or synthesized. These 
processes are classified into two branches: catabolic pathways that produce 
energy (namely adenosine triphosphate, ATP) and anabolic pathways that 
synthesize molecules and require energy expenditure. This metabolic network is 
tightly regulated in response to external stimuli through subsequent signaling 
pathways and both positive and negative allosteric control of rate-limiting enzymes. 
This allows for the rapid response to ever-changing cellular demands that vary 
based on cell type, microenvironment, and proliferative state (34).  Cancer cells 
reprogram metabolic pathways in order to fulfill the biosynthetic requirements 
associated with increased proliferation. Specifically, tumor cells alter their 








Figure 2. Summary of the noncanonical functions of Rb. Rb regulates several 
cellular processes relevant to cancer via interaction with numerous binding 
partners and transcription factors (33). Reprinted with permission from [Springer 
Nature] : [Nature] [NATURE REVIEWS CANCER] (Cellular mechanisms of 
tumour suppression by the retinoblastoma gene), (Deborah L. Burkhart and Julien 






or catabolism to maintain survival during nutrient deprivation (35). The 
dependencies on specific metabolic substrates exhibited by tumor cells are driven 
by specific oncogenes and tumor suppressor genes that promote or inhibit 
tumorigenesis, respectively. This reprogramming ability of tumor cells is 
recognized as one of the hallmarks of cancer by Drs. Hanahan and Weinberg and 
is now a field of extensive research (36). The major metabolic pathways that differ 
between cancer cells and non-transformed cells are described below.  
Glucose Metabolism and the Warburg Effect 
 To fulfill the biosynthetic demands of rapid proliferation, tumor cells must 
increase the import of nutrients from their environment. Increased glucose uptake 
is a distinguishing feature of tumor cells and is observed in most human cancers 
(34,37). This difference is widely exploited diagnostically in Positron Emission 
Tomography (PET) imaging where patients are administered radiolabeled analogs 
of glucose such as 18F-fluorodeoxyglucose to visualize tumors (37). Under 
physiologic oxygen concentrations, normal cells catabolize glucose to pyruvate, 
the end product of glycolysis, followed by its conversion to acetyl-CoA to fuel the 
tricarboxylic acid cycle (TCA cycle). The TCA cycle generates reduced 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide 
(FADH2) cofactors, which serve as a source of electrons for mitochondrial 
respiration and ATP (adenosine triphosphate) production. This process generates 
up to 36 ATP per molecule of oxidized glucose. In contrast, cancer cells, even in 
the presence of oxygen, preferentially use glycolysis to generate a larger fraction 




ATP per molecule of glucose (35-43). This phenomenon was first described by Dr. 
Otto Warburg and is referred to as “aerobic glycolysis” or the “Warburg effect”; 
wherein cancer cells increase glycolytic flux and divert pyruvate from the TCA 
cycle to generate lactate regardless of oxygen availability (44,45). This was 
originally postulated to result from mitochondrial dysfunction in cancer cells that 
necessitated the exclusive use of glycolysis for energy production. However, 
recent studies have shown intact tumors enhance both glycolysis and oxidative 
phosphorylation simultaneously to meet both the anabolic and bioenergetic 
demands of proliferation (35,46).  
To compensate for the lower energy yield, cancer cells increase both the 
rate of glucose uptake and glycolysis by increasing expression of glucose 
transporters and glycolytic enzymes (37,47). Additionally, increased glycolytic flux 
in cancer cells generates intermediates that are required to supply subsidiary 
anabolic pathways with the necessary substrates to support cell growth and 
proliferation (Figure 3). Both glucose-6-phosphate and fructose-6-phosphate 
serve as substrates for the pentose phosphate pathway (PPP), which generates 
the ribose moiety for nucleotide synthesis. Likewise, 3-phosphoglycerate 
participates in one-carbon metabolism, where it is converted to formate, an 
additional substrate for nucleotide synthesis. Glyceraldehyde-3-phosphate can be 
converted to glycerol-3-phosphate, the carbon backbone required to synthesize 
several types of lipids. Further, when glucose is catabolized by the TCA cycle, it 







Figure 3. Anabolic pathways support cancer cell growth. Increased glycolytic 
flux in cancer cells generates intermediates that serve as substrates for anabolic 
pathways such as nucleotide biosynthesis, lipid synthesis, and one-carbon 
metabolism to sustain cell growth. From [DeBerardinis, R. J., and Chandel, N. S. 
(2016) Fundamentals of cancer metabolism. Sci Adv 2, e1600200]. Reprinted with 






Lactate Metabolism  
 In normal cells, pyruvate is converted to acetyl-CoA to fuel the TCA cycle, 
yet cancer cells have been found to preferentially generate lactate from pyruvate. 
This is in part due to the upregulation of lactate dehydrogenase A (LDHA), which 
catalyzes pyruvate to lactate. This reaction  provides several selective advantages 
to cancer cells (39,48). Converting pyruvate to lactate regenerates NAD+ to allow 
for continued glycolytic activity through glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). Moreover, excretion of lactate into the tumor 
microenvironment lowers extracellular pH and increases the activity of 
metalloproteases, aiding in the degradation of the extracellular matrix and inducing 
cancer metastasis (49,50). Likewise, extracellular lactate promotes an 
immunosuppressive tumor microenvironment (51-53). 
Lactate is trafficked in and out of the cell by monocarboxylate transporters, 
MCT1 (import) and MCT4 (export). While cancer cells upregulate MCT4 and 
primarily export lactate (54), recent studies have reported circulating lactate can 
be imported through MCT1 and utilized as a TCA cycle carbon source in both 
mouse models of lung cancer as well as in NSCLC patients (37,55,56). The 
symbiosis of excreting and oxidizing imported lactate is postulated to allow glucose 
to supply other anabolic pathways for cell growth while sustaining the bioenergetic 
demands of rapid proliferation (43,57).  
Glutaminolysis 
In addition to glycolysis, cancer cells rely heavily on glutaminolysis to meet 




most abundant amino acid in the plasma and is consumed at significantly higher 
rates in cancer cells compared to normal tissue (47,58). Glutamine plays several 
key roles in cancer metabolism as a nitrogen donor for nucleotide and protein 
synthesis, a carbon source for lipid biosynthesis and energy production, and as a 
precursor for the production of glutathione (Figure 4) (58-60). Increased 
expression and activity of glutamine metabolizing enzymes and transporters have 
been reported in multiple cancers (42,61). Additionally, targeting glutamine 
utilization via glutamine depletion or inhibition of glutaminolytic enzymes has 
shown efficacy against glutamine-dependent cancer types in vitro and in vivo 
(47,61). 
Glutaminolysis is a series of biochemical reactions that initiates when 
glutamine is transported into the cytoplasm and is further metabolized through 
deamination reactions catalyzed by mitochondrial or cytosolic glutaminases to 
generate glutamate. In the cytoplasm, glutamine is used as a nitrogen donor for 
biosynthesis of purine and pyrimidine nucleotides, or as a carbon source through 
the conversion of glutamate for the antioxidant glutathione and nonessential amino 
acids (42). Many cancer cells require de novo lipid biosynthesis which diverts 
citrate from the TCA cycle to supply a source of lipogenic acetyl-CoA. Diminished 
availability of citrate to the TCA cycle as a consequence of the Warburg effect 
results in the need for anaplerotic replenishment of the TCA cycle, which can be 
provided by glutaminolysis (47). In the mitochondria, glutamate serves as a source 
of carbon for the TCA cycle, through production of alpha-ketoglutarate by 





Figure 4. Major metabolic and biosynthetic fates of glutamine. Glutamine 
plays several key roles in cancer metabolism as a nitrogen donor for nucleotide 
synthesis, a carbon source for lipid biosynthesis and energy production, and as a 
precursor for glutathione biosynthesis. Abbreviations: glutamine transporter 
(SLC1A5), glutaminase (GLS/GLS2), glutamate dehydrogenase (GLUD), 
reductive carboxylation (RC). Reprinted with permission from [Springer Nature] : 
[Nature] [NATURE REVIEWS CANCER] (From Krebs to clinic: glutamine 
metabolism to cancer therapy), (Brain J. Altman, Zachary E. Stine, and Chi V. 





aminotransferase (AAT), alanine aminotransferase (ALT), or phosphoserine 
aminotransferase (PSAT). Oxidative metabolism of glutamine through the TCA 
cycle also produces NADH and FADH2 for mitochondrial OXPHOS (oxidative 
phosphorylation) to generate ATP necessary to sustain cellular bioenergetics. 
Additionally, glutaminolysis allows cancer cells to mitigate oxidative stress 
associated with rapid cell proliferation. Glutamine carbons exiting the TCA cycle 
as malate are converted to pyruvate by malic enzyme, a reaction which generates 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) (62). NADPH is 
required for the generation of reduced glutathione, a reactive oxygen species 
scavenger that protects against oxidative stress.  
In addition to serving as a source of anaplerotic carbon for the TCA cycle, 
glutamine can also contribute to the production of acetyl-CoA for lipogenesis via 
reductive carboxylation. Acetyl-CoA production from glutamine occurs via two 
distinct mechanisms. First, the addition of CO2 to glutamine-derived a-
ketoglutarate via isocitrate dehydrogenase 1 (IDH1) produces citrate, which is 
transported to the cytosol to generate lipogenic acetyl-CoA (63). Likewise, 
glutamine-derived malate can be converted to pyruvate by malic enzyme, which 
can be further metabolized to lipogenic acetyl-CoA via citrate (47). Primarily 
observed under hypoxic conditions, reductive carboxylation of a-ketoglutarate 
provides a source of acetyl-CoA for lipogenesis that is independent of glucose, 
allowing cells to divert glucose carbons into other anabolic pathways for growth 
(64).  




Pentose phosphate pathway (PPP) is one of the major metabolic pathways 
that promotes tumor cell proliferation by generating the substrates necessary for 
nucleic acid synthesis to support DNA replication and RNA production. DNA and 
RNA are polymers composed of varying combinations of nucleotides, made up of 
an organic base (pyrimidines including cytosine, thymine, and uracil, and purines 
which include adenine and guanine), one or more phosphate groups, and a 
pentose sugar (ribose for RNA or deoxyribose for DNA). The major functions of 
the PPP are to generate ribose-5-phosphate, the pentose phosphate moiety for 
nucleotides, and generate NADPH through activity of glucose-6-phosphate 
dehydrogenase (G6PD) (37).  
 PPP is comprised of two branches. In the oxidative arm, the glycolytic 
intermediate glucose-6-phosphate is irreversibly converted to ribulose-5-
phosphate, yielding two molecules of NADPH. The non-oxidative arm is a 
reversible pathway comprised of carbon-exchanging reactions beginning with 
ribulose-5-phosphate and producing a final product of the glycolytic intermediates 
fructose-6-phosphate and glyceraldehyde-3-phosphate, which can participate in 
downstream metabolic pathways. Additionally, the non-oxidative arm produces 
ribose-5-phosphate (R5P) as an intermediate which is used in nucleotide 
synthesis. The regulatory enzymes that control the PPP include G6PD (oxidative 
branch) and transketolase (non-oxidative branch).  
 Rapidly proliferating cells have a high demand for nucleotides and other 
substrates for biosynthesis, therefore by providing NADPH and R5P for nucleotide 




sustaining their anabolic demands (65,66). In proliferating tumor cells, G6PD 
activity increases (67), and several PPP enzymes are reported to be upregulated 
in multiple cancer subtypes (68,69). Recent studies suggest that in addition to its 
proliferative role, the PPP has an important role in other aspects of cancer such as 
drug resistance, apoptosis, invasion, and metastasis (68), making the PPP a 
potential metabolic target for anti-cancer therapies.  
One-Carbon Metabolism 
One-carbon (1C) metabolism supports multiple physiological processes 
including the production of 1C units for nucleotide synthesis, methylation reactions, 
and the generation of reduced cofactors for redox homeostasis (70). 1C units are 
largely derived from serine and glycine, both non-essential amino acids which can 
be obtained exogenously or synthesized from other carbon sources (71). Serine 
can be synthesized de novo from glucose through a series of enzymatic reactions 
which convert 3-phosphoglycerate into serine, and glycine can be produced from 
serine or threonine. Upregulation of enzymes within serine synthesis as well as 
“serine addiction” has been observed in several human cancers (72). These 
substrates are utilized by two primary 1C metabolism pathways: the folate cycle 
and the methionine cycle (70). The folate cycle produces 1C units for nucleotide 
synthesis as well as NADPH for maintaining redox balance, and has been the 
target of many anti-cancer therapies (70). Conversely, the methionine cycle 





 Lipids are a broad category of hydrophobic or amphipathic molecules. 
These are comprised of triacylglycerides that primarily serve as energy storage, 
and phosphoglycerides, sterols, and sphingolipids, which are the major structural 
components of plasma membranes. The main constituents of triacylglycerides and 
phosphoglycerides are fatty acids, which consist of long hydrocarbon chains with 
a carboxy-terminal group. To sustain their high proliferative rate, tumor cells 
increase de novo lipid biosynthesis to supply the building blocks for membrane 
formation (73,74). Oncogenes specifically enhance lipogenesis through the 
upregulation of lipogenic enzymes such as ATP citrate lyase (ACLY), fatty acid 
synthase (FASN), and acetyl-CoA carboxylase (ACC), as well as by increasing the 
production of substrates for fatty acid synthesis (75-77). While tumor metabolic 
reprogramming involves an increase in lipogenesis, recent studies have 
highlighted a role for fatty acid oxidation in tumorigenesis (78). Fatty acids are a 
rich energy source as their degradation produces acetyl-CoA which can undergo 
mitochondrial oxidation, yielding large amounts of ATP through the TCA cycle and 
mitochondrial respiration (73,74). 
As stated previously, metabolic reprogramming is a hallmark of cancer that 
is characterized by upregulation of multiple pathways including glycolysis, 
glutaminolysis, PPP, one-carbon metabolism, and lipid metabolism. These specific 
pathways not only aid in meeting the energy demands of rapid proliferating tumor 
cells but supply the substrates to sustain large-scale biosynthesis. Additionally, the 
majority of key oncogenic or tumor suppressor pathways observed in human 




selective advantage. Elucidating the unique metabolic phenotype of cancer cells 
and the genetic drivers thereof allows for identification of new targets for the 
potential development of novel therapies to improve patient outcome.  
Metabolic Functions of pRb 
 Advances in our understanding of pRb function have highlighted roles that 
extend beyond the cell cycle. Specifically, recent studies demonstrate a direct role 
for pRb in controlling cellular metabolism in both normal and transformed cells. 
The results of these studies are discussed below.  
Glucose Metabolism 
The earliest studies to highlight a role for pRb in controlling glucose 
metabolism reported elevated expression and activity of hexokinase II (HK2), a 
rate limiting enzyme in glycolysis, in retinoblastomas compared to normal retina 
(79). Activation of pRb has also been shown to increase expression of several 
glycolytic genes in oncogene-induced senescent cells, promoting both glycolysis 
and OXPHOS (80). Notably, both glycolysis and OXPHOS were abolished upon 
knockdown of RB1, highlighting a direct role for pRb in glycolytic activation. In 
addition, genetic deletion of RB1 in retinal pigment epithelial cells decreases 
glucose oxidation (81).  
 Several studies using transgenic mouse models to modulate pRb/E2F 
pathway activity in vivo have demonstrated a role for pRb/E2F proteins in 
regulating glucose tolerance. Deletion of E2F1 in adipocytes results in resistance 
to diet-induced obesity (82), while loss of Rb1 in the hypothalamus leads to 




to promote pRb phosphorylation, thus increasing E2F activity in non-transformed 
tissues (84,85). Conversely, glucose deprivation promotes the accumulation of 
hypophosphorylated pRb in cultured mesangial cells (84). These data suggest that 
pRb itself can be regulated in part by changes in glucose levels.  
Nucleotide Synthesis 
Among the first direct E2F-regulated targets to be described included genes 
involved in nucleotide synthesis, such as dihydrofolate reductase (DHFR), 
thymidylate synthase (TS), ribonucleotide reductase (RNR), and thymidine kinase 
(TK1) (86,87). In the absence of pRb, the transcription of each of these genes 
increases suggesting regulation by an pRb/E2F complex (88). Additionally, E2F-
regulation of these targets is conserved during evolution, highlighting the 
significance of this pathway in regulating nucleotide synthesis (89-91). Several 
studies have shown a potential link between pRb-mediated control of nucleotide 
synthesis and cell cycle regulation. Expression of a constitutively active pRb 
protein results in both an increase in G1 cell population and a concomitant 
decrease in dNTP pools (88). Likewise, pRb, but not p107 or p130, was found to 
repress expression of RNR and DHFR in cells that had undergone oncogene-
induced senescence (92). Notably, knockdown of RB1 in these cells rescued the 
changes in gene expression and allowed the cells to reenter the cell cycle.  
Lipogenesis 
 Targets of the pRb/E2F pathway are often regulated by additional DNA-
binding proteins which modulate their gene expression. One study identified a 




(SREBP) transcription factors (93). SREBPs are master regulators of lipogenic and 
steroidogenic genes (94), thus demonstrating a new role for pRb in regulating lipid 
metabolism. pRb was reported to target many of the genes encoding enzymes 
within fatty acid and cholesterol biosynthesis (93). Moreover, the authors noted 
these genes possess either E2F-consensus sequences, sterol regulatory 
elements (SREs), or both. Lipidomic profiling coupled with transcriptomic analysis 
of mouse embryonic fibroblasts (MEFs) revealed loss of Rb1 induces significant 
alterations in their lipid composition and increases tumorigenic potential (95).  
The TCA Cycle and Oxidative Metabolism 
 The pRb/E2F complex directly regulates mitochondrial activity by 
suppressing the expression of enzymes that regulate mitochondrial pyruvate 
oxidation (96,97). Specifically, pyruvate dehydrogenase kinase (PDK4) is a direct 
target of pRb/E2F, and when activated, inhibits pyruvate dehydrogenase (PDH) 
activity, resulting in decreased glucose oxidation within the TCA cycle. Contrary to 
these findings, acute deletion of Rb1 in mice has been reported to increase 
mitochondrial pyruvate oxidation from glucose in both the lung and colon (81). 
Additionally, RB1 deficiency in triple negative breast cancers increases both 
OXPHOS and mitochondrial protein translation (98).  
In addition to glucose, cancer cells oxidize glutamine-derived carbon to fuel 
the TCA cycle (58,59,99). Increased glutaminolysis and glutathione production has 
been observed in pRb-deficient mammalian cells and Drosophila (91,100). 
Specifically, loss of Rb1 increases expression of the glutamine transporter ASCT2 




significantly increased ROS in these cells, suggesting pRb-deficient cells may be 
susceptible to oxidative stress upon glutaminase inhibition.  
While the mechanism by which pRb mediates metabolic changes has not 
been fully elucidated, several studies has reported that E2F and pRb proteins bind 
directly to promoters of genes that regulate metabolic flux (101). Moreover, pRb 
can also exert its metabolic function through directly decreasing expression of 
oncogenic signaling pathways that converge on metabolism, such as Ras or c-Myc 
(86). An important gap in the evidence for a model by which pRb directly regulates 
metabolism is that the majority of these studies were performed in non-transformed 
cells or tissues. To date, there is no published study that directly assesses the 
metabolic phenotype resulting from pRb dysfunction in lung cancer; particularly in 
vivo. Based on the growing body of evidence that pRb plays a role in regulating 
the metabolic state of the cell (86,87,95,102), we hypothesize that pRb modulates 
metabolism in lung cancer through control of specific genes within pathways that 
support cancer growth. This hypothesis will be examined by the following aims: 
• Specific Aim 1: Define the metabolic changes resulting from pRb 
activation in NSCLC in vitro. This aim will be evaluated in A549 lung 
adenocarcinoma cells and will implement several in vitro metabolic assays. 
pRb activation will be achieved pharmacologically using an FDA-approved 
CDK4/6 inhibitor.  
• Specific Aims 2 and 3: Characterize the changes in glucose utilization 
(Aim 2) and metabolism of other TCA nutrient substrates (Aim 3) 




will be evaluated using a combination of steady-state and stable-isotope 
labeled metabolomics to assess global changes in either glucose, 
glutamine, or lactate metabolism resulting from Rb1 loss in Kras-driven lung 























CHAPTER 2: PALBOCICLIB TREATMENT ALTERS NUCLEOTIDE 
BIOSYNTHESIS  AND GLUTAMINE DEPENDENCY IN A549 CELLS 
Introduction 
Lung cancer is among the most frequently diagnosed cancers and is the 
leading cause of cancer-related death worldwide, with an estimated 1.6 million 
deaths each year (1-3). Of its subtypes, non-small cell lung cancer (NSCLC) 
accounts for 85% of all lung cancer diagnoses (2). One of the hallmark events in 
NSCLC pathogenesis is deregulation of the cell cycle (18,103). Transition from G1 
to S phase during cell cycle progression is tightly regulated by phosphorylation of 
the retinoblastoma protein tumor suppressor (pRb) by the CDK4/6-Cyclin D 
complex. Activity of the CDK4/6-Cyclin D complex is strongly inhibited by p16 
which induces cell cycle arrest. In the majority of NSCLC cases, p16 is mutated, 
deleted, or epigenetically silenced, resulting in constitutive phosphorylation of pRb 
and uncontrolled cell cycle progression (18,103). Pharmacologically, CDK4/6 
inhibition phenocopies p16 activity (104,105).  
Highly selective and potent small-molecule CDK4/6 inhibitors have shown 
anti-tumor activity both in vitro and in vivo (104,105). Among these inhibitors, 
palbociclib (PD-0332991) has been FDA-approved for the treatment of women with 
breast cancer (21). Recently, palbociclib has shown efficacy either alone or as 




functional consequences of CDK4/6 inhibition apart from cell cycle arrest in 
NSCLC are largely unknown; yet metabolic reprogramming in response to 
palbociclib has revealed unique targetable vulnerabilities in several cancers 
including pancreatic, colorectal, and leukemia (106-108). As such, we aimed to 
characterize the metabolic phenotype induced by palbociclib in NSCLC.  
Herein, we report that palbociclib treatment decreases nucleotide 
biosynthesis and increases glutaminolysis without altering glycolysis in A549 lung 
adenocarcinoma cells. Specifically, palbociclib-induced glutamine dependency 
sensitizes A549 cells to glutaminase inhibition. Together, these data expand our 
knowledge of understanding of the metabolic consequences of CDK4/6 inhibition 
















Materials and Methods 
Cell culture  
 The A549 lung adenocarcinoma cells were obtained from ATCC and 
cultured in DMEM (Gibco) supplemented with 10% fetal bovine serum (Hyclone) 
and 50µg/ml gentamicin sulfate (Gibco). Cells were maintained at 5% CO2 at 37°C. 
Palbociclib (PD-0332991) and CB-839 were purchased from Selleck Chemicals.  
Cell transfections 
 Using Lipofectamine RNAiMAX reagent (Invitrogen), A549 cells were 
transiently transfected with control siRNA (Silencer Select Negative Control #2, 
Cat. No. 4390826, Ambion) or siRNA targeted to RB1 (Silencer Select s523, Cat. 
No. 4390824, Ambion) for 24 hours prior to palbociclib treatment.  
Cell proliferation and viability 
 A549 cells were seeded at 120,000 in 6-well plates (Corning), followed by 
transfection and treatment with 1µM palbociclib or vehicle control. For glutaminase 
inhibition studies, cells were seeded at 25,000 in 24-well plates (Corning), followed 
by 25nM CB-839 treatment. Forty-eight hours post-treatment, cell number was 
determined by trypan blue exclusion and enumeration using a hemocytometer.   
Glucose uptake 
  A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were 
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to 
performing the assay. Cells were then incubated in glucose-free DMEM for 30 min, 
followed by incubation with 5 µL of 2-[14C]-deoxyglucose (0.25µCi/ml; Perkin Elmer) 




collected in 500 µL of 0.1% SDS and scintillation counts (counts/min) were 
measured using 350 µL of cell lysate on a Tri-Carb 2910 liquid scintillation analyzer 
(Perkin Elmer Life Sciences). Protein concentration was determined using the BCA 
assay (Pierce) according to the manufacturer’s protocol. Counts were normalized to 
µg of protein.   
3H2O-Glycolysis Assay 
 A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were 
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to 
performing the assay. All cells were then incubated with 500 µL of complete medium 
containing 2 µL of 1µCi of 5-[3H]-glucose for 60 min. Medium was then collected and 
centrifuged for 5 min at 8,000 rpm to pellet cell debris. To isolate 3H2O generated 
via enolase activity from the 5-[3H]-glucose added to the medium, 150 µL of 
radiolabeled medium was added to open microcentrifuge tubes that were placed in 
airtight scintillation vials containing 1 mL of H2O. Vials were parafilm sealed, and 
3H2O from the medium was allowed to equilibrate with the H2O in the scintillation 
vials for 48 hours at 37°C. 3H2O that has diffused into the H2O was measured on a 
Tri-Carb 2910 liquid scintillation analyzer (Perkin Elmer Life Sciences). Protein 
concentration was determined using the BCA assay (Pierce) according to the 
manufacturer’s protocol. Counts were normalized to µg of protein.   
Mito stress test 
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were 
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to 




XFe96 analyzer according to manufacturer’s protocol. One day prior to preforming 
the assay, cells were reseeded at 35,000 in XFe96 cell culture plates and incubated 
in 5% CO2 at 37°C. One hour prior to analysis, growth medium was replaced with 
assay medium (DMEM minus phenol red and sodium bicarbonate that is  
supplemented with 1mM pyruvate, 2mM L-glutamine, and 10mM glucose, pH 7.4) 
and incubated in a non-CO2 incubator.  During assay, 1µM oligomycin (Sigma), 2µM 
FCCP (Sigma), and 1µM rotenone/antimycin A (Sigma) were sequentially injected 
into each well in accordance with standard protocols. Absolute rates (pmoles/min) 
were normalized to µg of protein.  
Mito fuel flexibility assay 
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were 
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to 
performing the assay. OCR measurements were conducted using a Seahorse 
XFe96 analyzer according to manufacturer’s protocol. One day prior to preforming 
the assay, cells were reseeded at 35,000 in XFe96 cell culture plates and incubated 
5% CO2 at 37°C. One hour prior to analysis, growth medium was replaced with 
assay medium (DMEM minus phenol red and sodium bicarbonate that is 
supplemented with 1mM pyruvate, 2mM L-glutamine, and 10mM glucose, pH 7.4) 
and incubated in a non-CO2 incubator. Capacity and dependency for fatty acid, 
glutamine, and glucose oxidation were determined through injections of the following 
inhibitors in accordance with standard protocols: 4µM etomoxir (inhibits long chain 
fatty acid oxidation), 3µM BPTES (inhibits glutamine oxidation), and 2µM UK5099 




determined by dividing the OCR following inhibiting the two other pathways by the 
OCR observed when all pathways are inhibited. The percent dependency for each 
fuel source was determined by dividing the OCR observed when that specific 
pathway is inhibited by the OCR observed when all pathways are inhibited.  Absolute 
rates (pmoles/min) were normalized to µg of protein. 
Glycolysis stress test 
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were 
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to 
performing the assay. ECAR measurements were conducted using a Seahorse 
XFe96 analyzer according to manufacturer’s protocol. One day prior to preforming 
the assay, cells were reseeded at 35,000 in XFe96 cell culture plates and incubated 
5% CO2 at 37°C. One hour prior to analysis, growth medium was replaced with 
assay medium (DMEM minus phenol red and sodium bicarbonate that is 
supplemented with 2mM L-glutamine, pH 7.4) and incubated in a non-CO2 
incubator.  During assay, 10mM glucose (Sigma), 1µM oligomycin (Sigma), and 
50mM 2-deoxyglucose (Sigma)  were sequentially injected into each well in 
accordance with standard protocols. Absolute rates (mpH/min) were normalized to 
µg of protein. 
Glucose 6-phosphate dehydrogenase activity assay 
A549 cells were seeded at 120,000 in 6-well plates (Corning). Cells were 
transfected and treated with 1µM palbociclib or vehicle control for 48 hours prior to 




the manufacturer’s protocol using the Glucose-6-Phosphate Dehydrogenase 
Activity Assay Kit (Sigma, Cat. No. MAK015-1KT) and normalized to µg of protein. 
[U-13C]-glucose tracer studies 
Cells were seeded at 1 x 106 cells in 10cm dishes (Corning) and treated 
with palbociclib or vehicle control for 48 hours. Cells were then labeled for six hours 
with DMEM supplemented with 1g/L [U-13C]-glucose and 10% dialyzed fetal bovine 
serum (Gibco). Cells were washed three times in ice-cold 1x PBS and quenched 
with acetonitrile. Metabolites were extracted in acetonitrile:water:chloroform 
(2ml:1mL:740µL). Samples were centrifuged at 3,000xg for 20 minutes at 4oC to 
separate the polar, lipid, and cell debris layers. The remaining cell debris was re-
extracted with 500µL chloroform:methanol:butylated hydroxytoluene (2:1:1 mM) 
and centrifuged at 22,000xg for 20 minutes at 4oC.  The residual polar and lipid 
fractions were combined with their respective fractions from the first extraction. 
The polar fraction was vacuum-dried by lyophilization. The dried sample was 
dissolved in 100 µL 50% acetonitrile and vigorously vortex-mixed for 3 minutes. 
After centrifugation at 14,000rpm and 4oC for 20 min, 80µL of supernatant was 
collected for 2DLC-MS/MS analysis.  
2DLC-MS/MS analysis and data processing     
All samples were randomly analyzed on a Thermo Q Exactive HF Hybrid 
Quadrupole-Orbitrap Mass Spectrometer coupled with a Thermo DIONEX 
UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). The 
UltiMate 3000 HPLC system was equipped with a reverse phase chromatography 




wwas configured in parallel to form a parallel 2DLC-MS system (109). To obtain 
full MS data, every sample was analyzed by the parallel 2DLC-MS in positive mode 
(+) and negative mode (-), respectively. For metabolite identification, one 
unlabeled sample in each sample group was analyzed by 2DLC-MS/MS in positive 
mode (+) and negative mode (-) to acquire MS/MS spectra at three collision 
energies (20, 40 and 60 eV). 
Data analysis for 2DLC-MS/MS       
Full MS .raw files were first converted to .mzML format with msConvert tool, 
a part of an open-source ProteoWizard suite, described in detail by Adusumilli and 
Mallick (110). Isotopologue peak deconvolution and assignments were performed 
using El-MAVEN (111). Peaks were assigned using a metabolite list generated 
and verified using full scan MS and MS/MS spectra of unlabeled samples, as 
described previously (112-114).  The metabolite list contained metabolite names 
and corresponding molecular formulae used to generate theoretical m/z values for 
all possible isotopologues, and retention times for each metabolite. El-MAVEN 
parameters for compound library matching were as follows: EIC Extraction Window 
±7 ppm; Match Retention Time ± 0.60 min. For 13C isotopologue peak detection, 
the software criteria were set as follows: Minimum Isotope-parent correlation 0.20; 
Isotope is within 5 scans of parent; Abundance threshold 1.0; Maximum Error To 
Natural Abundance 100%. All assignments were visually inspected and compared 
to unlabeled samples for reference. The peak list with corresponding abundances 
was exported to a comma-separated (CSV) file and uploaded to the Polly workflow 




metabolite (by summing peak areas of each detected isotopologue) using Polly 
Isocorrect module. Finally, the data were downloaded and plotted using Microsoft 
Excel and GraphPad Prism software. 
Real time-PCR 
Total RNA was isolated from cell pellets using the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s protocol. The resulting total RNA (1µg) was 
converted to cDNA using the High-Capacity RNA-to cDNA kit (applied biosystems). 
Gene expression was determined by qPCR using the following Taqman Gene 
Expression Assays: RB1 (Hs01078066_m1), RRM1 (Hs01040698_m1), RRM2 
(Hs00357247_g1), PRPS2 (Hs00267624_m1), G6PD (Hs0166169_m1), ASCT2 
(Hs01056542_m1), GLS (Hs01014020_m1), and GLUD1 (Hs01632647_g1). b-
actin (Hs01060665_g1) was used as an internal control. Data are reported as the 
log (base 2) of the fold change with respect to siNeg treated with vehicle control. 
Immunoblotting  
 Whole-cell lysates were prepared in RIPA lysis buffer (Pierce) containing 
protease and phosphatase inhibitors. 20 µg of protein was separated on 10% Bolt 
Bis-Tris gels (Invitrogen) and transferred to PVDF membrane. Membranes were 
blocked with 5% BSA in TBS-T and probed with 1:1000 dilution of anti-phospho-Rb 
(Cell Signaling, #3590S) overnight at 4oC. Membranes were washed and incubated 
with HRP-conjugated anti-rabbit (1:5,000) secondary antibodies for one hour. 
Protein detection was performed by ECL chemiluminescent reagent (Amersham) 
exposure. 1:20,000 dilution of anti-b-actin antibody (Sigma, A2228) was used to 





Statistical analyses were carried out using GraphPad Prism. All numerical 
data are reported as mean ± SEM. For each experiment, statistical analysis, 
























Palbociclib treatment does not alter glycolysis in A549 cells 
To assess the role of CDK4/6 inhibition on metabolism in NSCLC, we 
utilized A549 lung adenocarcinoma cells. While these cells express wild-type pRb,  
they harbor a p16INK4A deletion that results in constitutive pRb 
hyperphosphorylation and inactivation. Our prior studies have demonstrated 
treatment with palbociclib inhibits the phosphorylation of pRb and results in 
decreased cell proliferation (Figure 5A,B) (115). Recent studies have 
demonstrated palbociclib alters glucose metabolism in multiple cancer subtypes 
(116-118). To monitor the effect of palbociclib on glucose uptake, we performed 
radiolabeled glucose uptake assay using 2-[14C]-deoxyglucose in A549 cells. As 
CDK4/6 inhibition can have metabolic effects independent of pRb, these studies 
were performed following palbociclib treatment with simultaneous knockdown of 
RB1 (Figure 5C). We observed no significant change in glucose uptake upon 
palbociclib treatment in A549 cells (Figure 6A). We next examined, as a 
measurement of glycolytic activity, the release of 3H2O from 5-[
3H]-glucose via 
enolase activity. We found that palbociclib decreases 3H2O production in an pRb-
dependent manner (Figure 6B). However, it has been reported that the use of 5-
[3H]-glucose to measure glycolysis can overestimate glycolytic rate, as both the 
pentose phosphate pathway (PPP) and glycolysis generate the substrate for 
enolase (119). To better assess glycolytic function in response to palbociclib 
treatment, we performed a glycolysis stress test using a Seahorse XFe96 analyzer. 


















Figure 5. Palbociclib decreases pRb phosphorylation and proliferation of 
A549 lung cancer cells. (A) Western blot analysis phosho-pRb (p-pRb) levels and 
(B) cell proliferation A549 cells following 48-hour 1µM palbociclib treatment. (C) 
Confirmation of pRb knockdown by siRNA by qPCR. For (A,C) b-actin was used 
as a loading and internal control, respectively. For (B,C) values represent mean ± 
SEM, analyzed by unpaired t-test (n=5, independent experiments) (B) and two-
way ANOVA with Sidak’s post-hoc multiple comparisons (n=3, independent 
experiments) (C). Statistical significances between each group are as follows: 



























































Figure 6. Palbociclib has no effect on glucose uptake but decreases 3H2O 
production in an pRb-dependent manner. (A) Glucose uptake assessed by 
intracellular 2-[14C]-deoxyglucose, and (B) Enolase activity measured by 3H2O 
production in A549 cells following knockdown of pRb and 48-hour treatment with 
1µM palbociclib. Values represent mean ± SEM, analyzed by two-way ANOVA 
with Sidak’s post-hoc multiple comparisons (n=3, independent experiments). 









































upon palbociclib treatment (Figure 7), suggesting palbociclib does not alter 
glycolysis in A549 cells.   
To define global changes in glucose utilization resulting from palbociclib 
treatment, we performed [U-13C]-glucose tracer studies. Utilization of ubiquitously 
labeled glucose results in the intracellular generation of 13C labeling of the hexose 
and triose sugar intermediates within the glycolytic pathway; leading to fully labeled 
pyruvate (m+3) and lactate (m+3) (Figure 8). Palbociclib has been shown to 
increase glycolytic flux in both breast and pancreatic cancers (106,117,118); 
however, consistent with our glycolysis stress test findings, palbociclib does not 
alter glucose carbon incorporation into glycolytic intermediates in A549 cells 
(Figure 9). Our data suggest that the palbociclib-mediated effects on glycolysis 
may be tissue-specific.  
CDK4/6 inhibition decreases glucose flux through the PPP 
Given we observed a decrease in 3H2O production as measured from 
radiolabeled 5-[3H]-glucose, but did not observe a corresponding decrease in ECAR 
or glucose carbon incorporation into glycolytic intermediates from our [U-13C]-
glucose tracer studies, we hypothesized palbociclib may alter PPP activity. We 
observed decreased glucose carbon incorporation into sedoheptulose 7-
phosphate, an intermediate in the PPP. Treatment also decreased m+5 labeling of 
several nucleotides, which is indicative of a fully labeled ribose moiety derived from 
PPP activity (Figure 10,11). Together, these data suggest palbociclib decreases 




















Figure 7. Palbociclib does not alter glycolytic function in vitro. (A) Glycolysis 
stress test measured in A549 cells following knockdown of pRb and 48-hour 
treatment with 1µM palbociclib. (B-E) ECAR assessment of (B) glycolysis, (C) non-
glycolytic acidification, (D) glycolytic capacity, and (E) glycolytic reserve. Values 
represent mean ± SEM, analyzed by two-way ANOVA with Sidak’s post-hoc 






























































































































Figure 8. Cartoon of [U-13C]-glucose fate mapping though glycolysis. Red 

































Figure 9. Palbociclib does not alter glucose carbon incorporation into 
glycolytic intermediates in A549 cells. (A-F) Fractional enrichment of m+6 
labeled glucose 6-phosphate (A) and fructose 6-phosphate (B), and m+3 labeled 
3-phosphoglycerate (C), phosphoenolpyruvate (D), pyruvate (E), and lactate (F) 
following 48-hour treatment with 1µM palbociclib. Values represent mean ± SEM, 





































































































































Figure 10. Cartoon of [U-13C]-glucose fate mapping though the pentose 

















Figure 11. Palbociclib decreases glucose carbon incorporation into the PPP 
in A549 cells. (A) Fractional enrichment of m+5 labeled nucleotides and 
nucleosides, and (B) m+7 sedoheptulose 7-phosphate following 48-hour treatment 
with 1µM palbociclib. Values represent mean ± SEM, analyzed by unpaired 
student’s t-test (n=6, technical replicates). Statistical significances between each 

























































decreased glucose 6-phosphate dehydrogenase (G6PD) activity in an pRb-
dependent manner (Figure 12A). Additionally, we measured expression of G6PD 
and other genes within nucleotide synthesis including phosphoribosyl 
pyrophosphate synthetase 2 (PRPS2) and ribonucleotide reductase 1/2 (RRM1/2). 
Palbociclib decreased expression of RRM2 in an pRb-dependent manner but does 
not significantly alter expression of other genes within nucleotide synthesis (Figure 
12B-E).  
Palbociclib increases oxygen consumption in A549 cells 
 CDK4/6 inhibition has been reported to increase both mitochondrial mass 
and oxygen consumption in pancreatic cancer (106). As such, we assessed 
mitochondrial activity by measurement of the oxygen consumption rate (OCR) in 
A549 cells following palbociclib treatment. Consistent with other cancer types 
(106,107), we observed a significant increase in several parameters of 
mitochondrial activity including basal (p = 0.0019) and non-mitochondrial 
respiration (p = 0.0115) (Figure 13). While two-way ANOVA revealed no 
interaction between palbociclib treatment and pRb status (p = 0.113), palbociclib 
increased basal OCR 1.4-fold, which was reduced to 1.2-fold in the absence of 
pRb.  
To determine if the increase in basal oxygen consumption upon palbociclib 
treatment is the result of increased glucose oxidation, we measured TCA cycle 
metabolites following [U-13C]-glucose labeling in A549 cells. Pyruvate (m+3) 
generated from glycolysis can be metabolized to lactate by lactate dehydrogenase 

















Figure 12. Palbociclib decreases G6PD activity and RRM2 transcript levels 
in A549 cells. (A) G6PD activity assessed in A549 cells following knockdown of 
pRb and 48-hour treatment with 1µM palbociclib. (B-E) qPCR analysis of glucose 
6-phosphate dehydrogenase (G6PD), phosphoribosyl pyrophosphate synthetase 
2 (PRPS2), and ribonucleotide reductase 1/2 (RRM1/2) in A549 cells following 
knockdown of pRb and 48-hour treatment with 1µM palbociclib. Values represent 
mean ± SEM, analyzed by two-way ANOVA with Sidak’s post-hoc multiple 
comparisons (n=3, independent experiments). Statistical significances between 

























































































































Figure 13. Palbociclib increases mitochondrial respiration in A549 cells. (A) 
Oxygen consumption rate (OCR) measured in A549 cells following knockdown of 
pRb and 48-hour treatment with 1µM palbociclib. (B-G) OCR assessment of (B) 
basal respiration, (C) non-mitochondrial respiration, (D) maximal respiration (E) ATP 
production, (F) proton leak, and (G) spare capacity. Values represent mean ± SEM, 

































































































































































pyruvate carboxylase (PC). PDH entry of pyruvate carbon is indicated by m+2 (1st 
turn)/m+4 (2nd turn) isotopologues, while PC activity is observed by m+3 
isotopologue labeling of TCA intermediates. (Figure 14). While there was no 
consistent effect on PDH-mediated pyruvate carbon entry (m+2/m+4), we found 
that palbociclib increased m+3 labeling of several TCA metabolites, suggesting 
palbociclib increases PC activity for anaplerosis in A549 cells (Figure 15).  
Palbociclib sensitizes A549 cells to glutaminase inhibition in an pRb-
dependent manner 
 We next sought to determine whether palbociclib alters the capacity 
to metabolize or the dependency on specific TCA fuels such as glucose, glutamine, 
or fatty acids for mitochondrial function. We performed the Mito Fuel Flex assay 
using a Seahorse XFe96 analyzer to assess the contributions of glucose, 
glutamine, and fatty acids as fuel sources to maintain basal mitochondrial 
respiration. Palbociclib had no effect on the overall capacity of A549 cells to utilize 
glucose, but did decrease the cells’ dependency on glucose to maintain basal 
respiration, indicating glucose is not the sole fuel source for the TCA cycle in 
palbociclib treated cells (Figure 16A,D). While palbociclib increases the capacity 
to oxidize fatty acids, it has no effect on the cells’ dependency for fatty acid 
oxidation, suggesting that inhibition of fatty acid oxidation would have no effect on 
the viability of palbociclib treated cells (Figure 16B,E). Notably, we observed an 
increase in both glutamine capacity and dependency in A549 cells upon palbociclib 





















Figure 14. Cartoon of [U-13C]-glucose fate mapping through the 1st turn of the 
TCA cycle. Red circles are 13C labeling indicative of pyruvate dehydrogenase 
activity, green circles are 13C labeling indicative of pyruvate carboxylase activity, 
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Figure 15. Palbociclib increases PC-mediated anaplerosis in A549 cells. (A-
D) Fractional enrichment of the TCA metabolites (A) citrate, (B) fumarate, (C) 
malate, and (D) aspartate in A549 cells following 48-hour treatment with 1µM 
palbociclib. Values represent mean ± SEM, analyzed by unpaired student’s t-test 
for each metabolite isotopologue (vehicle vs. palbociclib) (n=6, technical 
replicates). Statistical significances between each group are as follows: 



















































































Figure 16. Palbociclib increases glutamine dependency in A549 cells. (A) 
glucose, (B) glutamine, and (C) fatty acid capacity, and (D) glucose, (E) glutamine, 
and (F) fatty acid dependency measured by the Mito Fuel Flex assay in A549 cells 
following 48-hour treatment with 1µM palbociclib. Values represent mean ± SEM, 
analyzed by unpaired student’s t-test (n=3, independent experiments). Statistical 



















































































































The enzyme glutaminase converts glutamine to glutamate and is highly 
expressed in cancer cells (58,59,62). CB-839 is a highly potent glutaminase 
inhibitor that has shown anti-tumor activity in both in vitro and in vivo models of 
lung cancer (120). We hypothesized that the observed increase in glutamine 
dependency may sensitize palbociclib treated cells to glutaminase inhibition. 
Although palbociclib does not significantly alter expression of genes within 
glutamine utilization, including the glutamine transporter, ACTS2, glutaminase 
(GLS), or glutamine dehydrogenase (GLUD1) (Figure 17), we observed a 
significant decrease in proliferation in cells treated with CB-839 and palbociclib, 
than with palbociclib or CB-839 alone (Figure 18). Additionally, statistical analysis 
found a significant interaction between inhibitor sensitivity and pRb status (p < 
0.0001), suggesting pRb expression is necessary for palbociclib to exert its effect 
on glutamine dependency. Together, our data highlight that palbociclib-induced 

























Figure 17. Palbociclib does not alter expression of genes within glutamine 
utilization. qPCR analysis of the glutamine transporter ASCT2, glutaminase 
(GLS), and glutamate dehydrogenase (GLUD1) in A549 cells following knockdown 
of pRb and 48-hour treatment with 1µM palbociclib. Values represent mean ± SEM, 




















Figure 18. Palbociclib sensitizes A549 cells to glutaminase inhibition. Cell 
proliferation following knockdown of pRb and 48-hour treatment with 1µM 
palbociclib and/or 25nM CB-839. Values represent mean ± SEM, analyzed by two-
way ANOVA with Sidak’s post-hoc multiple comparisons (n=3, independent 
experiments). Statistical significances between each group are as follows: 




































 While cancer metabolism as a target for therapeutic intervention has been 
extensively studied (35,38,42,48,61), there is a growing appreciation for cell cycle 
proteins that display metabolic regulatory functions (33,86,96,104,121). 
Additionally, with the increase in utilization of CDK4/6 inhibitors in the clinic, there 
is a need for better understanding of the metabolic consequences of CDK4/6 
inhibition. In the current study, we report that activation of pRb via treatment with 
the CDK4/6 inhibitor palbociclib in A549 lung adenocarcinoma cells results in a 
metabolic shift wherein palbociclib alters glucose and glutamine utilization. 
Specifically, palbociclib decreases glucose metabolism through the PPP via 
inhibition of G6PD activity (Figure 12A), while increasing glutaminolysis to 
maintain basal mitochondrial function (Figure 16B,E). Moreover, both changes 
observed were rescued upon knockdown of pRb, suggesting the metabolic 
consequences of CDK4/6 inhibition in A549 cells with respect to these metabolic 
processes are pRb-dependent. 
 Recently, it has been demonstrated that CDKs can directly regulate 
metabolism via phosphorylation of metabolic enzymes. Specifically, the cyclin 
D3/CDK6 kinase complex can phosphorylate pyruvate kinase M2 and 6-
phosphofructokinase (108). The authors report that this results in shunting of 
glycolytic intermediates into the PPP and the serine synthesis pathways. 
Treatment with palbociclib reduces this flux, resulting in NADPH and glutathione 
depletion and inducing apoptosis. Consistent with these findings, we observed a 




in part due to decreased activity of the rate limiting enzyme in the PPP, G6PD 
(Figure 12A). As A549 cells express both CDK4 and CDK6, it remains unclear 
whether the observed decrease in G6PD activity is due the effects of the cyclin 
D3/CDK6 kinase complex inhibition.  
As previously described, palbociclib increases mitochondrial activity in vitro 
(106,107). Specifically, CDK4/6 inhibition increases glutamine utilization and 
sensitivity to glutaminase inhibition in breast and colorectal cancer cells (107). The 
authors reported that the increase in glutaminolysis was a result of enhanced MYC 
signaling in response to CDK4/6 inhibition. We did observe a modest increase in 
basal oxygen consumption upon palbociclib treatment (Figure 13B), which is 
driven, in part, by enhanced glutaminolysis (Figure 16B,E). We postulate that this, 
in turn, sensitized A549 cells to treatment with CB-839 (Figure 18). MYC exerts 
its effect on glutaminolysis specifically via upregulation of the glutamine transporter 
ASCT2 and GLS (122,123). As we did not observe significant upregulation of these 
genes (Figure 17), our data suggest the enhanced glutaminolysis in this context 
may be independent of MYC signaling. 
While other studies have reported enhanced glycolysis upon CDK4/6 
inhibition or deletion, or direct activation of pRb itself (80,106,107), our [U-13C]-
glucose and ECAR studies revealed no significant changes in glycolytic function 
upon palbociclib treatment (Figure 6,7,9). One possible explanation for this 
discrepancy is the acute treatment duration for our studies (48 hours compared to 
120 hours). Prolonged CDK4/6 inhibition (96 hours to two weeks) has been 




Many of the reported metabolic consequences of palbociclib treatment are also 
metabolic hallmarks of these cellular processes. Senescent cells exhibit elevated 
glycolysis and mitochondrial metabolism, resulting in increased mitochondrial 
mass and production of reactive oxygen species (ROS) (126,127). This triggers 
autophagy and protein degradation to mitigate the cellular stress induced by 
senescence (128). In addition to enhanced glycolysis, palbociclib treatment has 
been reported to increase amino acid catabolism, mitochondrial abundance and 
activity, and ROS production (106,107). Our studies are unique in that we have 
identified potential senescence-independent metabolic consequences of CDK4/6 
inhibition.  
 Given the recent use of palbociclib in clinical trials for NSCLC patients, 
understanding the noncanonical functions CDK4/6 inhibition in cancer cell 
metabolism are important for identifying potential combination therapies to improve 
patient outcome. Our studies demonstrate that palbociclib treatment increases 
glutamine dependency and sensitizes cells to the glutaminase inhibitor, CB-839. 
While the precise mechanism by which palbociclib mediates increased 
glutaminolysis remains unclear, pRb expression is required for palbociclib to exert 
its function in this context. Together, our data highlight the metabolic changes upon 
palbociclib treatment in A549 cells and may support the of targeting CDK4/6 
inhibition in combination with glutaminase inhibitors in NSCLC patients with pRb-




CHAPTER 3: LOSS OF RB1 ENHANCES GLYCOLYTIC METABOLISM IN 
KRAS-DRIVEN LUNG TUMORS IN VIVO 
Introduction 
Lung cancer is the leading cause of cancer-related deaths for both men and 
women worldwide, with the 5-year survival rate being less than 18% (1). Of its 
subtypes, non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer 
diagnoses (2). Deregulation of the cell cycle is a major driver of tumorigenesis, and 
aberrant expression of cell cycle proteins in the retinoblastoma protein, E2F factor 
(pRb-E2F) pathway have been found to play a key role in the pathogenesis of 
NSCLC (18,103). pRb is a tumor suppressor that is reported to be dysfunctional in 
the majority of human cancers. Canonically, pRb functions to regulate cell cycle 
progression by repressing the transcriptional activity of the E2F family of 
transcription factors, inhibiting S phase entry (129). In most NSCLC cases, pRb 
inactivation occurs via hyperphosphorylation; however, in 15-30% of cases, Rb1, 
the gene encoding pRb, is mutated, which correlates to poorer overall survival for 
these patients (33,130).  
Advances in our understanding of pRb function have highlighted additional 
biochemical pathways under pRb regulation beyond cell cycle progression. 
Emerging evidence supports a direct role for pRb in regulating metabolic pathways 




phosphorylation, and reactive oxygen species metabolism (86,87,95,102). pRb 
can exert its metabolic function via interaction with the E2F family of transcription 
factors and altering expression of metabolic enzymes and transporters (81,96,97). 
Additionally, acute loss of Rb1 increases mitochondrial pyruvate oxidation in 
normal lung tissue; however, the metabolic effects of pRb loss during lung cancer 
development are largely unknown.  
Herein, we report that loss of Rb1 in an in vivo mutant Kras-driven model of 
lung cancer enhances glycolytic metabolism without altering mitochondrial 
pyruvate oxidation. Moreover, loss of Rb1 has no significant effect on TCA 
anaplerosis or utilization of alternative nutrient sources apart from glucose. These 
data expand our knowledge of understanding of the metabolic phenotype resulting 















Materials and Methods 
Mouse model and adenoviral infection 
All animal studies were approved by the University of Louisville’s 
Institutional Animal Care and Use Committee. KrasLSL/G12D/Rb1+/+ and 
KrasLSL/G12D/Rb1lox/lox mice were generated by breeding KrasLSL/G12D/Rb1+/lox mice 
as described in (131). Lung tumors were induced in 8-week old KrasLSL/G12D/Rb1+/+ 
and KrasLSL/G12D/Rb1lox/lox mice by intratracheal instillation of 2.5x107 PFU of 
adenovirus expressing Cre-recombinase (Vector Development Lab, Baylor 
College of Medicine). For all studies, age-matched non-instilled 
KrasLSL/G12D/Rb1lox/lox mice were used as normal lung controls.   
Kaplan-Meier analysis 
Eight-weeks post-surgery, KrasLSL/G12D/Rb1+/+ and KrasLSL/G12D/Rb1-/- mice 
were examined twice weekly. Mice were sacrificed upon visible signs of advanced 
morbidity such as lethargy, weight loss (>15%), hunching, and distressed rapid 
breathing. The logrank P value and hazard ratio (HR) was calculated using Kaplan-
Meier survival analysis in GraphPad Prism software.  
[U-13C]-glucose, [U-13C, 15N]-glutamine, and [U-13C]-lactate tracer studies 
Upon tumor onset (KrasLSL/G12D/Rb1-/-: 10-16 weeks; KrasLSL/G12D/Rb1+/+: 
15-20 weeks; determined by symptomatic observation of labored breathing) mice 
were injected via the tail vein with either 80µL 25%w/v [U-13C]-glucose or 200µL 
of 36.2 mg/ml [U-13C, 15N]-glutamine, three times, 15 minutes apart as described 
in (132,133). [U-13C]-lactate studies were performed following the same protocol 




were sacrificed by cervical dislocation, blood collected, and lung tumors or normal 
lung were excised and flash frozen in liquid nitrogen. Number of animals per group 
(normal lung, Rb1+/+, and Rb1-/- lung tumors) for each labeled nutrient is depicted 
within their respective figure legends.  
Plasma [U-13C]-glucose, [U-13C, 15N]-glutamine, and [U-13C]-lactate analysis 
Blood was collected from mice by cardiac puncture following euthanasia 
and processed as described in (133). Up to 150µL of blood was collected in K2-
EDTA microtubes and incubated at room temperature for 5 minutes, then placed 
on ice. Plasma was separated from blood cells by centrifugation at 3,500xg for 15 
minutes at 4oC. For [U-13C]-glucose and [U-13C]-lactate studies, plasma was 
deproteinized by trichloroacetic acid (TCA) extraction by adding 300µL of 1:10 TCA 
dilution to 30µL plasma. Samples were centrifuged at 15,000rpm for 30 minutes at 
4oC and the supernatant was vacuum dried by lyophilization. Samples were 
redissolved in 650µL D2O and analyzed by 2D-NMR. For [U-
13-C, 15N]-glutamine 
studies, metabolites were extracted from plasma by adding 130µL methanol:water 
(80:20) to 10µL plasma. Samples were vortexed for 10 seconds, incubated for 10 
minutes at 4oC, followed by centrifugation at 16,000xg for 10 minutes at 4oC. The 
supernatant was vacuum dried by SpeedVac, followed by 2DLC-MS/MS analysis.  
Metabolite tissue sample preparation for tracer studies  
To extract metabolites from tissue samples, up to 20mg of pulverized frozen 
tissue was extracted for polar and lipid metabolites as described in (132) with minor 
modifications. In brief, metabolites were extracted in acetonitrile:water:chloroform 




separate the polar, lipid, and tissue debris layers. The remaining tissue debris was 
re-extracted with 500µL chloroform:methanol:butylated hydroxytoluene (2:1:1 mM) 
and centrifuged at 22,000xg for 20 minutes at 4oC.  The residual polar and lipid 
fractions were combined with their respective fractions from the first extraction. 
The polar fraction was vacuum-dried by lyophylization. The dried sample was 
dissolved in 100 µL 50% acetonitrile and vigorously vortex-mixed for 3 minutes. 
After centrifugation at 14,000rpm and 4oC for 20 min, 80µL of supernatant was 
collected for 2DLC-MS/MS analysis.  
Sample preparation and derivatization for steady-state metabolomics 
Up to 20mg of pulverized frozen tissue was extracted in 1ml of 50% 
methanol and separated into polar (aqueous layer), and 
protein/DNA/RNA/glycogen pellet. The polar fraction was dried at 10-3 mBar using 
a SpeedVac (Thermo) followed by derivatization. The protein/DNA/RNA/glycogen 
pellet was washed 4 times with 50% methanol and once with 100% methanol. 
Samples were centrifuged at 15,000rpm for 10 minutes between washes. 
Hydrolysis of the protein/DNA/RNA/glycogen pellet was performed by first 
resuspending the dried pellet in diH2O followed by the addition of equal parts 2N 
HCl. Samples were vortexed thoroughly and incubated at 95°C for 2 hours. The 
reaction was quenched with 100% methanol with 40µM L-norvaline (as an internal 
control). The sample was incubated on ice for 30 minutes and the supernatant was 
collected by centrifugation at 15,000rpm at 4°C for 10 minutes. The collected 




Dried polar and hydrolyzed pellet samples were derivatized by the addition 
of 50µl of 20mg/ml methoxyamine in pyridine to the dried sample in the 1.5ml 
Eppendorf tube. Samples were incubated for 1 hour and 30 minutes at 30°C. 
Tubes were then centrifuged at 15,000rpm for 10 minutes. Supernatant of each 
tube was transferred to v-shaped amber glass chromatography vial. Lastly, 
addition of 80ul N-methyl-trimethylsilyation (MSTFA) occurred with an incubation 
period at 37oC for 30 minutes. Derivatized samples were then analyzed by GC-
MS.  
GC-MS analysis and data processing 
GC-MS protocols were similar to those described previously (134,135) 
except a modified temperature gradient was used for GC: Initial temperature was 
130°C, held for 4 minutes, rising at 6°C/minute to 243°C, rising at 60°C/minute to 
280°C, held for 2 minutes. The electron ionization (EI) energy was set to 70 eV. 
Scan (m/z:50-800) and full scan mode were used for metabolomics analysis. Mass 
spectra were translated to relative metabolite abundance using the Automated 
Mass Spectral Deconvolution and Identification System (AMDIS) software 
matched to the FiehnLib metabolomics library (available through Agilent) for 
retention time and fragmentation pattern matching with a confidence score of > 80 
(136-138). Data was further analyzed using the Data Extraction for Stable Isotope-
labelled Metabolites (DEXSI) software package (139). Relative abundance was 
corrected for recovery using the L-norvaline and adjusted to protein input. Rapid 
quantitation of derivatized protein/DNA/RNA/glycogen pellet is as described in 




levels was performed using the online Morpheus software tool from the Broad 
Institute.  
2DLC-MS/MS analysis and data processing     
All samples were randomly analyzed on a Thermo Q Exactive HF Hybrid 
Quadrupole-Orbitrap Mass Spectrometer coupled with a Thermo DIONEX 
UltiMate 3000 HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). The 
UltiMate 3000 HPLC system was equipped with a reverse phase chromatography 
(RPC) column and a hydrophilic interaction chromatography (HILIC) column that 
was configured in parallel to form a parallel 2DLC-MS system (109). To obtain full 
MS data, every sample was analyzed by the parallel 2DLC-MS in positive mode 
(+) and negative mode (-), respectively. For metabolite identification, one 
unlabeled sample in each sample group was analyzed by 2DLC-MS/MS in positive 
mode (+) and negative mode (-) to acquire MS/MS spectra at three collision 
energies (20, 40 and 60 eV). 
Data analysis for 2DLC-MS/MS       
Full MS .raw files were first converted to .mzML format with msConvert tool, 
a part of an open-source ProteoWizard suite, described in detail by Adusumilli and 
Mallick (110). Isotopologue peak deconvolution and assignments were performed 
using El-MAVEN (111). Peaks were assigned using a metabolite list generated 
and verified using full scan MS and MS/MS spectra of unlabeled samples, as 
described previously (112-114).  The metabolite list contained metabolite names 
and corresponding molecular formulae used to generate theoretical m/z values for 




parameters for compound library matching were as follows: EIC Extraction Window 
±7 ppm; Match Retention Time ± 0.60 min. For 13C isotopologue peak detection, 
the software criteria were set as follows: Minimum Isotope-parent correlation 0.20; 
Isotope is within 5 scans of parent; Abundance threshold 1.0; Maximum Error To 
Natural Abundance 100%. All assignments were visually inspected and compared 
to unlabeled samples for reference. The peak list with corresponding abundances 
was exported to a comma-separated (CSV) file and uploaded to the Polly workflow 
for natural abundance correction and calculation of total pool size for each 
metabolite (by summing peak areas of each detected isotopologue) using Polly 
Isocorrect module. Finally, the data were downloaded and plotted using Microsoft 
Excel and GraphPad Prism software. 
NMR analysis 
NMR spectra were recorded at 293 K at 14.1T initially on a Varian Inova 
NMR spectrometer with a 5 mm HCN cold probe and later on a Bruker Advance 
Neo NMR spectrometer equipped with a 5 mm Prodigy probe. Typically, pre-
saturation at very low power was employed in a pulse sequence during the recycle 
delay (3 seconds) to saturate any residual water (HOD) in the samples before 
acquiring for about 2 seconds. Generally, 256 scans were performed on each 
sample for signal averaging for better signal to noise ratio. Labelled and unlabeled 
lactate and glucose concentrations were measured by simple integration of the 
peak(s) areas of these metabolites relative to the known concentration of DSS 




sample which serves as both chemical shift reference and metabolite 
quantifications. 
Real time-PCR 
Total RNA was isolated from up to 30mg of frozen pulverized tissue using the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. The resulting 
total RNA (1µg) was converted to cDNA using the High-Capacity RNA-to cDNA kit 
(applied biosystems). Gene expression was determined by qPCR using the 
following Taqman Gene Expression Assays:), Cs (Mm00466043_m1), Idh2 
(Mm00612429_m1), Ogdh (Mm01179923_m1), Suclg1 (Mm00451244_m1), Sdha 
(Mm01352366_m1), Fh1 (Mm01321349_m1), Mdh2 (Mm00725890_s1), Asct2 
(Mm00436603_m1), Gls (Mm01257297_m1), Glud1 (Mm00492353_m1), Mct1 
(Mm01306379_m1), and b-actin (Mm00607939_s1) b-actin was used as an internal 
control. Data are reported as the log (base 2) of the fold change.  
Immunohistochemistry 
Mice were sacrificed by cervical dislocation and lungs were harvested, fixed 
overnight in 4% paraformaldehyde, and paraffin embedded. Lung tissue sections 
were dewaxed and rehydrated, followed by antigen retrieval in Tris-EDTA buffer (pH 
9.0). Sections were then blocked using 5% goat serum and incubated with 1:100 
dilution of the following antibodies overnight at 4oC: Glut1 (ProteinTech Cat. No. 
21829-1-AP), Hk2 (Cell Signaling Cat. No. 2867S), and Pkm2 (Cell Signaling Cat. 
No. 4053S). Sections were subsequently incubated with 1:500 dilution of HRP-
conjugated anti-rabbit antibody (Invitrogen Cat. No. 32260) for one hour at room 




counterstained with hematoxylin. Hematoxylin and eosin staining was performed 
by the University of Louisville’s Special Procedures Laboratory within the 
Department of Pathology. Imaging was performed using an Aperioscope digital 
slide scanner.  
Immunoblotting 
Protein lysate was generated from three distinct lung tumors from both the 
Kras/Rb+/+ and Kras/Rb-/- mice. 20µg of tumor or MCF-7 (positive control) protein 
lysate were separated by 10% SDS-PAGE followed by transfer to PVDF 
membrane. After transfer, membranes were cut between the 85kDa and 64kDa 
molecular weights for simultaneous assessment of either pRb, p107, and GAPDH 
using anti-RB (Cell Signaling #9309, 1:1000), p107 (ProteinTech 13354-1-AP, 
1:500), and GAPDH (Millipore ABS16, 1:500) antibodies, respectively. Proteins 
were visualized using 1:5000 dilution of either anti-mouse or -rabbit HRP-linked 
secondary antibody and ECL prime chemiluminescent reagent (Amersham).   
Statistical Analysis 
Statistical analyses were carried out using GraphPad Prism. All numerical 
data are reported as mean ± SEM. Grouped analysis was performed using One-
way ANOVA with Tukey’s post-hoc comparison. For each experiment, replicates 









Steady-state metabolomics highlights metabolic discrepencies in pRb-
deficient tumors in vivo 
Loss of Rb1 accelerates lung tumor progression in mutant Kras-driven lung 
cancer in vivo resulting in the development of higher-grade adenocarcinomas and 
decreased overall survival (131). Based on the emerging evidence that pRb 
directly regulates metabolism, we hypothesized loss of Rb1 promotes a metabolic 
phenotype that supports tumor progression. We have utilized a combination of 
steady-state and stable-isotope labeled metabolomics to assess global changes 
in metabolism resulting from pRb dysfunction in Kras-driven lung tumors in vivo 
(Figure 19A).  
Consistent with previous findings, loss of Rb1 significantly decreased 
overall survival and increased tumor burden in this Kras-driven lung cancer model 
(Figure 19B,C, 20). To identify potential pRb-dependent metabolic adaptations in 
these lung tumors, we performed steady-state metabolomics analysis to analyze 
the relative abundance of metabolites within major metabolic pathways. 
Hierarchical clustering demonstrated distinct metabolic patterns between normal 
lung, Rb1+/+, and Rb1-/- lung tumors (Figure 21). Interestingly, glucose-6-
phosphate, fructose-6-phsophate, glyceraldehyde-3-phosphate, and metabolites 
within the pentose phosphate pathway (ribose-5-phosphate) appear to be elevated 
in the Rb1-/- lung tumors. This suggests that pRb may regulate glucose utilization 








Figure 19. Loss of Rb1 accelerates lung cancer progression in a Kras-driven 
model of lung cancer. (A) Schematic of experimental design to assess the 
metabolic function of pRb in Kras-driven lung tumors in vivo. For all experiments, 
non-instilled KrasLSL/Rb1lox/lox mice served as normal lung controls. (B) Kaplan-
Meier survival analysis for KrasLSL mice with wild-type (Rb1+/+) (n=53) or knockout 
(Rb1-/-) (n=47) of Rb1. (C) Representative H&E staining of lung tissue from normal, 




















Figure 20. Confirmation of loss of Rb1 in resulting Kras-driven lung tumors. 
(A) Western blot analysis of pRb and p107 in three separate lung tumors after 
intratracheal instillation of Ad-Cre in either the Kras/Rb1+/+ or Kras/Rb1-/- mice. 
While pRb expression is relatively low in all developing lung tumors, elevated p107 
confirms loss of Rb1 in the Kras/Rb1-/- tumors as has been previously 
demonstrated for this model (15). MCF-7 cell lysate was used as a positive control 

























Figure 21. Rb1 loss qualitatively alters the steady state relative abundance 
of metabolites in Kras-driven lung tumors. Hierarchical clustering analysis 
depicts the relative abundance of metabolites in normal lung, Rb1+/+, and Rb1-/- 
lung tumors (n=4). Color coding indicates the row minimum or maximum for each 




abundance were observed within glycolysis or metabolic pathways originating from 
glycolytic intermediates.  
Loss of Rb1 enhances glycolysis in Kras-driven lung tumors 
To examine differences in glucose utilization between Rb1+/+ and Rb1-/- lung 
tumors, we preformed [U-13C]-glucose tracer studies. Sufficient [U-13C]-glucose 
plasma enrichment was observed for both normal lung and tumor bearing mice 
(Figure 22A). Utilization of ubiquitously labeled glucose results in the intracellular 
generation of 13C labeling of the hexose and triose sugar intermediates within the 
glycolytic pathway; resulting in fully labeled pyruvate (m+3) (Figure 23) . Pyruvate 
can then be metabolized to lactate by lactate dehydrogenase (LDH), 
transaminated to alanine by alanine aminotransferase (ALT), or enter TCA cycle 
through pyruvate dehydrogenase (PDH) or pyruvate carboxylase (PC). It has been 
previously shown that Kras-driven lung tumors display similar labeling of pyruvate 
and lactate compared to adjacent lung (46). Consistent with these findings, 
labeling of glycolytic intermediates from glucose carbon did not significantly differ 
in Rb1+/+ tumors compared to normal lung tissue (Figure 24). Conversely, loss of 
Rb1 significantly increased glucose carbon incorporation into several glycolytic 
intermediates, including both pyruvate and lactate (Figure 24C,D). 
We next sought to determine if the observed increase in carbon labeling of 
glycolytic intermediates in Rb1-/- lung tumors was due to changes in expression of 
rate-limiting enzymes in Kras-driven lung tumors. We performed 
immunohistochemitry analysis for glucose transporter 1 (Glut1), hexokinase 2 






















Figure 22. Rb1-/- mice exhibit increased labeled plasma glucose and lactate 
when administered [U-13C]-glucose. Fractional enrichment of fully labeled 
glucose (m+6) (A) and lactate (m+3) (B) in plasma from control, Rb1+/+ and Rb1-/- 
mice. For (A, B), values represent mean +/- SEM analyzed by one-way ANOVA 
with Tukey’s post-hoc comparison (normal lung n=3, Rb1+/+ n=12; Rb1-/- n=10). 



















































































Figure 23. Cartoon of [U-13C]-glucose fate mapping though glycolysis. 























Figure 24. Loss of Rb1 increases glucose carbon incorporation into 
glycolytic intermediates in vivo. (A-D) Fractional enrichment of m+6 labeled 
glucose 6-phosphate (A), and m+3 labeled 3-phosphoglycerate (B), pyruvate (C), 
and lactate (D) in normal lung, Rb1+/+, and Rb1-/- lung tumors following bolus [U-
13C]-glucose injections. Values represent mean ± SEM analyzed by one-way 
ANOVA with Tukey’s post-hoc comparison (normal lung n=3, Rb1+/+ n=12; Rb1-/- 
n=10). Statistical significances between each group are as follows: *p<0.05, 
























































































found that loss of Rb1 qualitatively increases Glut1, Hk2, and Pkm2 in Kras-driven 
lung tumors compared to those with intact pRb and normal lung tissue (Figure 
25).These results indicate that pRb enhances glycolysis, in part, via upregulation 
of glycolytic enzymes in Kras-driven lung tumors in vivo.  
As stated earlier, pyruvate carbon can enter the TCA cycle via two distinct 
mechanisms. Pyruvate can enter the TCA cycle as acetyl-CoA generated from the 
pyruvate dehydrogenase complex (PDH), or via anaplerosis in which pyruvate 
enters the TCA cycle as oxaloacetate through the activity of pyruvate carboxylase 
(PC) (Figure 26). PDH entry of pyruvate carbon is indicated by m+2 (1st turn)/m+4 
(2nd turn) isotopologues, while PC activity is observed by m+3 isotopologue 
labeling of TCA intermediates. Kras-driven lung tumors utilize pyruvate as the 
primary source of TCA cycle carbon via PDH and exhibit elevated PC activity 
(46,141). Consistent with these studies, we observed increased m+2 and m+4 
carbon labeling in certain intermediates as well as m+3 aspartate, malate, and 
fumarate in Rb1+/+ lung tumors compared to normal lung tissue (Figure 27). As 
several studies have demonstrated a role for the pRb-E2F pathway in regulating 
oxidative metabolism (81,96,97,142), we sought to define if loss of Rb1 further 
contributes to pyruvate oxidation in Kras-driven lung tumors. Interestingly, we 
observed no significant difference in both PDH or PC-mediated pyruvate carbon 
entry into the TCA cycle between Rb1+/+ and Rb1-/- lung tumors in vivo (Figure 
27). Moreover, loss of Rb1 does not alter gene expression of TCA cycle enzymes 








Figure 25. Loss of Rb1 increases expression of key glycolytic enzymes in 
Kras-driven lung tumors in vivo. Immunohistochemical staining examining 
glucose transporter 1 (Glut1), hexokinase 2 (Hk2), and pyruvate kinase M2 (Pkm2) 
expression in normal lung, Rb1+/+, and Rb1-/- lung tumors. Images were taken 
under 20x magnification and the scale bar in the lower left corner of each image 
























Figure 26. Cartoon of [U-13C]-glucose fate mapping through the 1st turn of the 
TCA cycle. Red circles are 13C labeling indicative of pyruvate dehydrogenase 
activity, green circles are 13C labeling indicative of pyruvate carboxylase activity, 
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Figure 27. Loss of Rb1 does not affect pyruvate metabolism in Kras-driven 
lung tumors in vivo. (A-F) Fractional enrichment of TCA metabolites in normal 
lung, Rb1+/+, and Rb1-/- lung tumors (normal lung n=3, Rb1+/+ n=12; Rb1-/- n=10). 
Values represent mean +/- SEM analyzed by one-way ANOVA with Tukey’s post-
hoc comparison. Statistical significances between each group are as follows: 

































































































































Figure 28. Loss of Rb1 does not affect gene expression of TCA cycle 
enzymes in Kras-driven lung tumors in vivo. qPCR analysis of the TCA cycle 
genes citrate synthase (Cs), isocitrate dehydrogenase 2 (Idh2), alpha-
ketoglutarate dehydrogenase (Ogdh), succinate-CoA ligase alpha subunit 
(Suclg1), succinate dehydrogenase complex, subunit a (Sdha), fumarate 
hydratase 1 (Fh1), and malate dehydrogenase 2 (Mdh2), in normal lung, Rb1+/+, 
and Rb1-/- lung tumors (n=4). Expression was normalized to b-actin and reported 
as the log (base 2) of the fold change. Values represent mean +/- SEM analyzed 



























lung tumors suggests loss of Rb1 enhances glycolysis without altering 
mitochondrial pyruvate oxidation in vivo. 
pRb does not regulate glutamine utilization in vivo 
Although it has been demonstrated that Kras-driven lung tumors do not 
utilize glutamine in vivo (46), loss of Rb1 has been shown to increase glutamine 
utilization as a source of anaplerotic carbon for the TCA cycle in mouse embryonic 
fibroblasts (MEFs) (100). As such, we sought to examine differences in glutamine 
utilization between Rb1+/+ and Rb1-/- lung tumors using [U-13C,15N]-glutamine 
tracer studies (Figure 29). Under three sequential bolus doses, we observed low 
plasma [U-13C, 15N]-glutamine and intracellular labeled glutamine and glutamate 
for both normal lung and tumor bearing mice (Figure 30A,B). As has been 
previously reported for Kras-driven lung tumors (46), we found no significant 
increase in glutamine anaplerosis into TCA cycle intermediates compared to 
normal lung. Interestingly, pRb-deficient tumors did not exhibit significantly 
different labeling of TCA cycle intermediates compared to Kras-driven lung tumors 
or normal lung tissue (Figure 30C). In addition to serving as a fuel source for the 
TCA cycle, cancer cells can metabolize glutamine via reductive carboxylation to 
citrate, producing acetyl-CoA via citrate lyase for lipogenesis (Figure 31A) 
(64,143). We observed no significant difference in m+5 citrate generated from the 
fixation of unlabeled CO2 to a-ketoglutarate (Figure 31B) (144), suggesting pRb 
function does not significantly contribute to reductive carboxylation of glutamine. 
Consistent with our labeling data, we did not observe any significant expression 



















Figure 29. Cartoon of [U-13C,15N]-glutamine fate mapping through the TCA 

































Figure 30. Loss of Rb1 does not influence glutaminolysis in vivo. (A) 
Fractional enrichment of fully labeled glutamine (m+5) in plasma from control, 
Rb1+/+ and Rb1-/- mice. (B) Fractional enrichment of fully labeled glutamine (m+5) 
and glutamate (m+5) in normal lung, Rb1+/+, and Rb1-/- lung tumors following bolus 
[U-13C,15N]-glutamine injections. (C) Fractional enrichment of m+4 TCA 
metabolites in normal lung, Rb1+/+, and Rb1-/- lung tumors. Values represent mean  
+/- SEM analyzed by analyzed by one-way ANOVA with Tukey’s post-hoc 
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Figure 31. Loss of Rb1 does not influence reductive carboxylation in vivo. 
(A) Cartoon of [U-13C,15N]-glutamine fate mapping through reductive 
carboxylation. Red circles are 13C and white circle are unlabeled 12C. Fractional 
enrichment of m+5 labeled citrate (B) in normal lung, Rb1+/+, and Rb1-/- lung tumors 
following bolus [U-13C,15N]-glutamine injections. Values represent mean  +/- SEM 
























within glutamine utilization including the glutamine transporter (Asct2), 
glutaminase (Gls), or glutamate dehydrogenase (Glud1) (Figure 32). Together, 
our findings suggest Rb1 does not appear to influence glutamine utilization in the 
context of Kras-driven lung cancer in vivo.  
Loss of Rb1 does not alter lactate utilization in Kras-driven lung tumors  
Recent studies have reported circulating lactate can be utilized as a TCA 
cycle carbon source in both Kras-driven lung tumors in vivo as well as in NSCLC 
patients (55,56). Given loss of Rb1 does not alter mitochondrial pyruvate oxidation 
in animals administered labeled glucose (Figure 27), we hypothesized loss of Rb1 
may influence  the utilization of circulating lactate. For these studies, we developed 
a labeling protocol using [U-13C]-lactate based on the method used for our [U-13C]-
glucose and [U-13C,15N]-glutamine tracer studies. In brief, three bolus doses of [U-
13C]-lactate were administered via tail vein injection, each 15 minutes apart. Fifteen 
minutes after the last injection, mice were euthanized and lung tumors or normal 
lung tissue was harvested for metabolite extraction followed by 2DLC-MS/MS 
analysis. Using this approach, plasma 13C-lactate was undetectable in both normal 
lung and tumor bearing mice when euthanized 15 minutes after the last injection. 
This is likely in part due to the high turnover rate for circulating lactate (56). To 
confirm [U-13C]-lactate was being rapidly turned over, we euthanized mice at 0, 5, 
or 10 minutes after the third dose of [U-13C]-lactate. When euthanized immediately, 
plasma 13C-lactate reached ~15%, then rapidly decreased by 5 and 10 minutes 














Figure 32. Genetic deletion of Rb1 does not regulate genes within glutamine 
utilization in vivo. qPCR analysis of glutamine transporter (Asct2), glutaminase 
(Gls), and glutamate dehydrogenase (Glud1) in normal lung, Rb1+/+, and Rb1-/- 
tumors.  Expression was normalized to b-actin and reported as the log (base 2) of 
the fold change. Values represent mean +/- SEM analyzed by analyzed by one-




































Figure 33. Rb1 deletion does not affect lactate carbon oxidation in Kras-
driven lung tumors in vivo. (A) Fractional enrichment of fully labeled lactate 
(m+3) in plasma from control mice following bolus [U-13C]-lactate injections. Mice 
were euthanized immediately (0 minutes), 5, or 10 minutes after the last injection 
(n=2 for each time point). (B) Fractional enrichment of fully labeled lactate (m+3) 
and pyruvate (m+3) in normal lung, Rb1+/+, and Rb1-/- lung tumors following bolus 
[U-13C]-lactate injections (n=4). Values represent mean +/- SEM analyzed by 



















































labeling of lactate-derived metabolites (Figure 34, 33B). Although tumor bearing 
and normal lung mice exhibited similar levels of m+3 lactate and pyruvate (Figure 
33B), we observed increased m+2 and m+3 labeling of several TCA cycle 
intermediates consistent with Kras-driven lung tumors exhibiting increased lactate 
utilization as a nutrient source for the TCA cycle (Figure 34, 35). However, loss of 
Rb1 did not significantly alter the extent of metabolite labeling. Consistent with our 
labeling data, while Kras-driven lung tumors exhibit elevated monocarboxylate 
transporter 1 (MCT1: lactate import),  loss of Rb1 does not further alter expression 
of MCT1 (Figure 36). These data suggest that pRb does not contribute to the 




































Figure 34. Cartoon of [U-13C]-lactate fate mapping through the 1st turn of the 
TCA cycle. Red circles are 13C labeling indicative of pyruvate dehydrogenase 
activity, green circles are 13C labeling indicative of pyruvate carboxylase activity, 


































Figure 35. Loss of Rb1 does not affect lactate carbon oxidation in Kras-
driven lung tumors in vivo. Fractional enrichment of TCA metabolites in normal 
lung, Rb1+/+, and Rb1-/- lung tumors (n=4). Values represent mean +/- SEM 
analyzed by analyzed by one-way ANOVA with Tukey’s post-hoc comparison. 
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Figure 36. Genetic loss of Rb1 does not regulate lactate import in vivo. qPCR 
analysis of monocarboxylate transporter 1 (Mct1) in normal lung, Rb1+/+, and Rb1-
/- tumors.  Expression was normalized to b-actin and reported as the log (base 2) 
of the fold change. Values represent mean +/- SEM analyzed by analyzed by one-
way ANOVA with Tukey’s post-hoc comparison (n=4). Statistical significances 































In the current study, we report that loss of Rb1 in mutant Kras-driven lung 
tumors leads to a metabolic shift in which pRb-deficient tumors display enhanced 
glycolysis presumably via upregulation of the glucose transporter Glut1 and two 
rate-limiting enzymes in glycolysis, Hk2 and Pkm2 (Figure 21). Interestingly, the 
increase in labeled glycolytic intermediates in Rb1-/- tumors compared to Rb1+/+ 
tumors was not observed in downstream metabolites within the TCA cycle. This 
was unexpected as studies have previously shown that Rb1 deletion results in 
increased TCA cycle activity and mitochondrial activation in non-cancer tissues in 
vivo (81,145). Conversely, other studies have reported that the pRb/E2F1 axis 
directly controls PDH activity by modulating the expression of pyruvate 
dehydrogenase kinase 4, suggesting loss of Rb1 function should decrease glucose 
flux into the TCA cycle (96,97). Although we observed a significant increase in m+3 
pyruvate labeling from glucose in pRb-deficient tumors, we found no 
accompanying increase in labeling of TCA intermediates between Rb1-/- and 
Rb1+/+ tumors (Figure 27); but a similar increase in labeled lactate. Additional 
tracer studies to examine lactate utilization also yielded no significant difference in 
labeling of TCA cycle intermediates in pRb-deficient tumors compared to those 
with intact pRb.  
 It has recently been suggested that the decoupling of mitochondrial 
oxidative phosphorylation from glycolysis provides a selective advantage to cancer 
cells to sustain cell proliferation (55,56). Enhanced conversion of pyruvate to 




while the use of circulating lactate for mitochondrial respiration operates in parallel 
to support the energetic functions of the TCA cycle (55). Our studies support the 
use of lactate as a nutrient oxidative fuel within the mitochondria of Kras-driven 
tumors as has been previously reported (55). We found substantial labeling in 
circulating lactate in the plasma of animals administered [U-13C]-glucose (m+3 40-
45%). We further observed similar labeling patterns of TCA intermediates from 
mice administered either bolus [U-13C]-glucose or [U-13C]-lactate (Figure 27,35); 
wherein loss of Rb1 had no significant effect. The disparity in overall labeling 
enrichment in TCA intermediates between either glucose or lactate administration 
is postulated to be due to differences in the levels of circulating labeled lactate 
produced under these bolus dosing conditions. The use of circulating lactate as a 
fuel for the TCA cycle may allow glucose to supply other anabolic pathways for cell 
growth. Specifically, glucose serves as a carbon source for the synthesis of 
nucleotides, amino acids, and lipids for biomass accumulation (43,57). pRb has 
been reported to regulate nucleotide metabolism via its interaction with E2F family 
members (86). The observed increase in aerobic glycolysis in pRb-deficient tumors 
could be to sustain nucleotide synthesis; however, the labeling duration used in 
our tracer studies was not sufficient to see incorporation of glucose carbon into 
nucleotides, therefore additional studies will need to be performed to assess the 
role of pRb in regulating nucleotide metabolism in vivo. Overall, our data indicate 
that loss of Rb1 enhances glycolysis but does not influence pyruvate oxidation in 




 The role of pRb in immunity has been well described (146,147), with recent 
studies demonstrating pRb inactivation recruits tumor-associated macrophages 
and immunosuppressive myeloid derived suppressor cells within the tumor 
microenvironment (148). This was found to be due to increased 
cytokine/chemokine secretion through altered AMP-activated protein kinase 
signaling from increased fatty-acid oxidation. These studies strongly suggests a 
tumor-derived metabolic contribution in regulating the immune landscape. Beyond 
the effects on cell proliferation, tumor-cell derived lactate produced during aerobic 
glycolysis has a profound effect on the tumor microenvironment and cancer 
progression (53). Extracellular lactate has deleterious effects on infiltrating T cells 
while serving as a nutrient source for immunosuppressive tumor-associated 
macrophages (51-53). pRb-deficient tumors exhibit increased lactate production 
from glucose (Figure 22B), yet whether this influences the immune response in 
the tumor microenvironment remains unclear.  
 Loss of Rb1 in vitro promotes glutamine utilization via upregulation of the 
glutamine transporter Asct2 and glutaminase in MEFs (100). However, this 
phenomenon was not observed in vivo. pRb-deficient Kras-driven tumors do not 
exhibit significant differences in glutamine carbon labeling of TCA cycle 
intermediates compared to lung tumors with intact pRb, nor do they increase 
expression of genes essential for glutamine utilization (Figure 30-32) . It has been 
reported that while glutamine strongly contributes to oxidative metabolism in 
cultured cells, circulating glutamine is not utilized as a primary fuel source for TCA 
anaplerosis in vivo, particularly in Kras-driven lung tumors (46). This may explain, 
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in part, the discrepancy in glutamine utilization between the MEF and transgenic 
lung tumor model and suggest the metabolic functions of pRb may be dependent 
on the in vivo environment of tumor cells.   
Our studies demonstrate a role for pRb in regulating glycolytic metabolism 
in Kras-driven lung tumors in vivo. Using both steady-state metabolomics and 
stable-isotope tracer studies, we report that loss of Rb1 enhances glycolysis 
without altering mitochondrial pyruvate oxidation. Additionally, our studies 
demonstrate pRb does not regulate glutamine anaplerosis in vivo. Together, our 
data highlights a metabolic phenotype resulting from pRb dysfunction in Kras-
driven lung tumors and may support the targeting of glycolytic metabolism in 
NSCLC patients with pRb-deficient tumors. 
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
This body of work highlights a role of pRb in mediating metabolic 
reprogramming in lung cancer. Specifically, activation of pRb via treatment with 
the CDK4/6 inhibitor palbociclib results in a metabolic shift in lung adenocarcinoma 
cells. We found that palbociclib decreases glucose metabolism through the PPP 
via inhibition of G6PD activity, while increasing dependency on glutaminolysis to 
maintain basal mitochondrial function (Chapter 2). While the precise mechanism 
by which palbociclib mediates its metabolic functions remain unclear, its effect on 
glucose and glutamine utilization in cultured A549 NSCLC cells were observed to 
be pRb-dependent as deletion of RB1 mitigated the effects of the inhibitor. 
Although it has been demonstrated that glutaminolysis is not a preferential 
anaplerotic carbon source for the TCA cycle in untreated or unchallenged Kras-
driven lung tumors in vivo (46), glutaminase inhibition combined with standard 
therapy has shown efficacy in preclinical models of lung cancer (120,149,150). It 
would be beneficial to confirm these in vitro demonstrated metabolic effects in an 
in vivo model under palbociclib mediated pRb manipulation. Together, our data 
may support targeting CDK4/6 inhibition in combination with glutaminase inhibitors 
in NSCLC patients with pRb-proficient tumors. 
In other studies, we have also demonstrated that genetic depletion of Rb1 
in a mutant Kras-driven mouse model of lung cancer enhances glucose 
95 
metabolism, via upregulation of key enzymes within glycolysis, without altering 
mitochondrial pyruvate oxidation (Chapter 3). One caveat to note for these studies 
is the observed difference in lung tumor pathology between Kras/Rb1+/+ and 
Kras/Rb1-/- mice. Kras/Rb1+/+ mice primarily develop lung adenomas, whereas loss 
of Rb1 has been shown to promote greater adenocarcinoma development, which 
more closely phenocopies human NSCLC (131). The metabolic adaptations that 
occur during progression from lung adenoma to adenocarcinoma are largely 
unknown, but we cannot rule out the possibility that this maybe a contributing factor 
to the metabolic differences observed between pRb-proficient and -deficient 
tumors in our model. Further technical advances will be necessary to address this 
concern. To date there is no available protocol to separate adenoma from 
adenocarcinoma for the metabolic analysis described in these results. Yet, many 
of the metabolic changes observed in human lung cancer patients (described 
below) are evident within these mouse models.  
While aerobic glycolysis is a known feature of cancer cells, targeting this 
pathway for therapy has proven challenging due to the cytotoxicity of many anti-
glycolytic agents (151). Biguanides, such as metformin and phenformin, are 
common therapeutics for the treatment of type 2 diabetes and have recently been 
reported to exhibit anti-cancer activity in vitro and in vivo (152-154). Specifically, 
both agents have an inhibitory effect on glycolysis and oxidative metabolism. The 
addition of metformin to standard therapy for lung adenocarcinoma patients 
significantly improves patient outcome (155), while phenformin inhibits tumor 
growth and angiogenesis in preclinical models of Kras-driven NSCLC (156). As it 
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extends to this body of work, our data suggest patients with pRb-deficient lung 
tumors (15-30% of NSCLC cases) may further benefit from combination therapy 
that are inclusive of either metformin or phenformin treatment. This strategy can 
be incorporated into future studies in defining therapeutic response of metabolic 
disruptors in these mouse models in order to support the translational potential of 
these findings.  
Additionally, it would be of interest to expand this work into NSCLC patient 
samples. There have been previous reports of metabolic changes in human 
NSCLC following labeled glucose administration. Consistent with our in vivo 
findings, patient lung tumors display elevated enrichment of lactate and TCA cycle 
metabolites compared to adjacent lung, indicating enhanced glucose oxidation 
(157,158). Interestingly, less perfused lung tumors rely heavily on glucose, 
whereas highly perfused regions utilize other fuel sources such as amino acids 
(158). This is primarily thought to be driven by the hypoxic environment within the 
individual tumors and further underscores the heterogenous nature of human 
NSCLC. However, no genotypic analysis of pRb status in these lung tumor 
samples was reported. We would expect that defining the potential pRb status in 
these samples would aid in correlating the patient results to those presented in our 
mouse model.  
Comparison of our in vitro and in vivo studies raises a conflicting question 
as to why our in vitro findings of pRb dysfunction are not recapitulated in vivo and 
vice versa? First, we observed changes in glutaminolysis in A549 cells under 
palbociclib treatment, but manipulation of Rb1 in lung tumors in vivo did not alter 
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glutamine utilization. Second, our in vivo data show that loss of Rb1 enhances 
glucose utilization, but palbociclib-induced activation of pRb in vitro had no effect 
on glycolysis. The most likely reason for this discrepancy lies in the metabolic 
differences between cultured cells and cells found within an in vivo environment. 
As stated above, solid tumors are comprised of a heterogeneous population of 
cells that include malignant cancer cells, immune cells, and stromal fibroblasts, all 
of which contribute to metabolic remodeling within the tumor microenvironment 
(159,160). Likewise, poor vasculature in solid tumors alters nutrient and oxygen 
availability, conditions which are not recapitulated in normal 2D cell culture. This 
phenomenon is highly relevant to our studies, as Kras-driven lung tumor cells have 
been shown to exhibit differential nutrient utilization when grown ex vivo, switching 
form glucose oxidation to a reliance on glutaminolysis in culture (46). Assessment 
of palbociclib treatment in this model of Kras-driven lung tumor would be beneficial 
in determining whether the in vitro metabolic functions of palbociclib can be 
recapitulated in vivo.  
Another potential reason for the metabolic discrepancies between our in 
vitro and in vivo data could be in the approach to assessing pRb function. In vitro, 
we utilized an approach of drug mediated pRb re-activation in Kras-driven lung 
cancer cells that harbor wild-type pRb, that is rendered inactive by 
hyperphosphorylation. Conversely, our in vivo studies used a model of genetic 
deletion of Rb1 that occurred at the point of tumor initiation. While the precise 
mechanisms are unknown, many studies have shown that inactivation of pRb does 
not phenocopy Rb1 deletion (15,161,162). This has also been demonstrated 
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clinically, as inactivation of pRb confers a selective advantage to specific types of 
cancer over RB1 loss. Recently, it was demonstrated that loss of RB1 in prostate 
cancer is necessary for disease progression, yet pRb function remains intact in the 
early stages of prostate cancer (163). Notably, the authors reported alterations in 
E2F1 transcriptional networks elicited by RB1 deletion that were distinct from those 
observed following phosphorylation-induced pRb inactivation. It seems feasible 
that the alterations in the transcriptomes and downstream signaling pathways 
between drug-induced activation of functional pRb in our in vitro studies and 
complete genetic loss of Rb1 within the in vivo models may contribute to their 
distinct metabolic phenotypes.  
Prior studies have shown pRb can directly regulate metabolism via its 
interaction with E2F (82,83,96,97,100), wherein the pRb/E2F complex regulates 
the expression of target metabolic genes. However, pRb/E2F also can regulate the 
expression of the components of oncogenic signaling pathways that participate in 
metabolic reprogramming. Specifically, c-MYC is a known pRb/E2F target gene, 
and can regulate many of the metabolic pathways we observed to be dysregulated 
in our in vitro and in vivo studies such as glycolysis, nucleotide metabolism, and 
glutaminolysis (164).  Lastly, pRb can also drive metabolic alterations independent 
of cell cycle machinery. For example, pRb can exert its effect on lipid metabolism 
via interaction with SREBPs to increase expression of genes within lipogenesis 
(93). Due to its wide-ranging ability to bind to over 100 proteins, many of which are 
transcription factors or chromatin modifying enzymes, it would be of interest to 
99 
characterize both the transcriptome and interactome for pRb in our models to 
define precisely how pRb mediates metabolic reprogramming in lung cancer.   
While more studies are needed to fully define the exact mechanisms by 
which pRb exerts its control over cellular metabolism, this body of work expands 
our knowledge of the metabolic phenotype resulting from pRb dysfunction in lung 
cancer. It also underscores the specific metabolic perturbations defined by pRb 
status that may potentially confer increased efficacy to targeted metabolic 
therapies for lung cancer patients.  
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